WO2024092106A2 - N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof - Google Patents
N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof Download PDFInfo
- Publication number
- WO2024092106A2 WO2024092106A2 PCT/US2023/077879 US2023077879W WO2024092106A2 WO 2024092106 A2 WO2024092106 A2 WO 2024092106A2 US 2023077879 W US2023077879 W US 2023077879W WO 2024092106 A2 WO2024092106 A2 WO 2024092106A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- dmt
- film
- acid
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 251
- 238000000034 method Methods 0.000 title claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000000651 prodrug Substances 0.000 claims abstract description 14
- 229940002612 prodrug Drugs 0.000 claims abstract description 14
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 claims description 227
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 38
- 239000011159 matrix material Substances 0.000 claims description 34
- 238000001228 spectrum Methods 0.000 claims description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 235000015165 citric acid Nutrition 0.000 claims description 18
- 239000006172 buffering agent Substances 0.000 claims description 17
- 229920002807 Thiomer Polymers 0.000 claims description 16
- 239000004014 plasticizer Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 15
- 239000003086 colorant Substances 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 12
- 235000010980 cellulose Nutrition 0.000 claims description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 210000003296 saliva Anatomy 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000002269 analeptic agent Substances 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 239000003961 penetration enhancing agent Substances 0.000 claims description 10
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 230000009477 glass transition Effects 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- -1 L-Glutahione Chemical compound 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000011975 tartaric acid Substances 0.000 claims description 8
- 235000002906 tartaric acid Nutrition 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 208000024714 major depressive disease Diseases 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 6
- 238000005266 casting Methods 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 229920000058 polyacrylate Polymers 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- 235000010449 maltitol Nutrition 0.000 claims description 5
- 239000000845 maltitol Substances 0.000 claims description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 5
- 229940035436 maltitol Drugs 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 229960004063 propylene glycol Drugs 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 235000019408 sucralose Nutrition 0.000 claims description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims description 4
- 102000004856 Lectins Human genes 0.000 claims description 4
- 108090001090 Lectins Proteins 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000002523 lectin Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 229940074982 poly(vinylpyrrolidone-co-vinyl-acetate) Drugs 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000004384 Neotame Substances 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001744 Sodium fumarate Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 3
- 239000000619 acesulfame-K Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 239000003833 bile salt Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000010630 cinnamon oil Substances 0.000 claims description 3
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 claims description 3
- 229940109275 cyclamate Drugs 0.000 claims description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940113120 dipropylene glycol Drugs 0.000 claims description 3
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims description 3
- 229960004756 ethanol Drugs 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229940040102 levulinic acid Drugs 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 235000019412 neotame Nutrition 0.000 claims description 3
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 3
- 108010070257 neotame Proteins 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 claims description 3
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 claims description 3
- 235000019477 peppermint oil Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 235000019204 saccharin Nutrition 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 229940081974 saccharin Drugs 0.000 claims description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 3
- 229940005573 sodium fumarate Drugs 0.000 claims description 3
- 235000019294 sodium fumarate Nutrition 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical group OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- 229940029039 propylene glycol alginate ester Drugs 0.000 claims description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001433 sodium tartrate Substances 0.000 claims description 2
- 229960002167 sodium tartrate Drugs 0.000 claims description 2
- 235000011004 sodium tartrates Nutrition 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 2
- 239000004201 L-cysteine Substances 0.000 claims 1
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- 244000263375 Vanilla tahitensis Species 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 208000012902 Nervous system disease Diseases 0.000 abstract description 9
- 208000025966 Neurological disease Diseases 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 description 58
- 229920000642 polymer Polymers 0.000 description 33
- 230000035699 permeability Effects 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- 230000001337 psychedelic effect Effects 0.000 description 22
- 238000004090 dissolution Methods 0.000 description 20
- 239000008186 active pharmaceutical agent Substances 0.000 description 18
- 210000005178 buccal mucosa Anatomy 0.000 description 17
- 238000000634 powder X-ray diffraction Methods 0.000 description 17
- 229920006254 polymer film Polymers 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 239000003196 psychodysleptic agent Substances 0.000 description 11
- 229940002226 buccal film Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000003232 mucoadhesive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- 229950002454 lysergide Drugs 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000008240 homogeneous mixture Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 5
- 238000000807 solvent casting Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 4
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 4
- 229960002237 metoprolol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000007928 solubilization Effects 0.000 description 4
- 238000005063 solubilization Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 244000017106 Bixa orellana Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical class OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000012665 annatto Nutrition 0.000 description 2
- 239000010362 annatto Substances 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WTPBXXCVZZZXKR-UHFFFAOYSA-N baeocystin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCNC)=CNC2=C1 WTPBXXCVZZZXKR-UHFFFAOYSA-N 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004106 carminic acid Substances 0.000 description 2
- 235000012730 carminic acid Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940080423 cochineal Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229940050411 fumarate Drugs 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000000380 hallucinogen Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
- 229940028444 muse Drugs 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008601 oleoresin Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 2
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 2
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- PVXVWWANJIWJOO-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine Chemical compound CCNC(C)CC1=CC=C2OCOC2=C1 PVXVWWANJIWJOO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- 206010050013 Abulia Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- OBSYBRPAKCASQB-UHFFFAOYSA-N Episalvinorin A Natural products COC(=O)C1CC(OC(C)=O)C(=O)C(C2(C3)C)C1(C)CCC2C(=O)OC3C=1C=COC=1 OBSYBRPAKCASQB-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 238000012357 Gap analysis Methods 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000883511 Lophophora williamsii Species 0.000 description 1
- QMMZSJPSPRTHGB-UHFFFAOYSA-N MDEA Natural products CC(C)CCCCC=CCC=CC(O)=O QMMZSJPSPRTHGB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241001145996 Psychotria viridis Species 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000012981 Traumatic Stress disease Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940114077 acrylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- RHGUXDUPXYFCTE-ZWNOBZJWSA-N ergoline Chemical class C1=CC([C@@H]2[C@H](NCCC2)C2)=C3C2=CNC3=C1 RHGUXDUPXYFCTE-ZWNOBZJWSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 238000012495 forced degradation study Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000022676 rumination Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- OBSYBRPAKCASQB-AGQYDFLVSA-N salvinorin A Chemical compound C=1([C@H]2OC(=O)[C@@H]3CC[C@]4(C)[C@@H]([C@]3(C2)C)C(=O)[C@@H](OC(C)=O)C[C@H]4C(=O)OC)C=COC=1 OBSYBRPAKCASQB-AGQYDFLVSA-N 0.000 description 1
- IQXUYSXCJCVVPA-UHFFFAOYSA-N salvinorin A Natural products CC(=O)OC1CC(OC(=O)C)C2(C)CCC34CC(CC3(C)C2C1=O)(OC4=O)c5occc5 IQXUYSXCJCVVPA-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Definitions
- N-N-DIMETHYL TRYPTAMINE (DMT) AND DMT ANALOG COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF
- the present disclosure relates to novel N,N-dimethyltryptamine (hereinafter ‘'DMT”) compositions and methods of treating neurological diseases and conditions.
- 'DMT N,N-dimethyltryptamine
- the disclosure provides improved pharmaceutical compositions comprising DMT in a form that permits controlled transmucosal release of DMT suitable for treatment of neurological diseases and conditions.
- Lysergic acid diethylamide (“LSD”), psilocybin and DMT are serotonergic agents often referred to as “classical hallucinogens” or “psychedelics,” and have the ability to induce qualitatively altered states of consciousness, such as euphoria, trance, transcendence of time and space, spiritual experiences, or dissolution of self-boundaries, while other effects such as sedation, narcosis, or excessive stimulation are only minimal.
- serotonergic psychedelics are either phenylalkylamines or indoleamines. with the indoleamine class being divided into two subsets, ergolines and try ptamines.
- Naturally occurring psychedelics such as the DMT, which is contained in the South American shrub Psychotria viridis, psilocybin, which is contained in over 200 mushroom species, or mescaline, which is contained in the Peyote cactus of the American Southwest and Northern Mexico, have been used for centuries by indigenous cultures in ritualistic or sociocultural contexts, and in the context of religious sacraments. While an unspecific “healing” potential had been ascribed to the use of naturally occurring psychedelics in those settings, more scientific investigations into their potential therapeutic application for defined diseases had not been pursued until after the discovery of the synthetic ergoline lysergic acid diethylamide (“LSD”) in 1943.
- LSD synthetic ergoline lysergic acid diethylamide
- the second concept was coined as "psychedelic therapy” and it emphasized the ability of psychedelics given at relatively high single doses to induce so called “peak psychedelic experiences.” Peak experiences are predominantly characterized by the loss of judgment to time and space and the dissolution of ego boundaries, which often culmmates in the experience of a blissful state and feelings of being a whole and harmonious existence in the cosmic unity.
- the basic mechanism considered in the psychedelic approach was therefore to produce a unique, overwhelming experience with an intuitive perception of psychological integration and harmony and subsequent self-improvements and enhanced joy in living and a sense of inner peace.
- DMT is also understood to hold therapeutic value as a psychedelic, with efficacy trials ongoing to assess the effect of DMT or DMT fumarate administered intravenously to subjects with major depressive disorder (“MDD”).
- MDD major depressive disorder
- DMT has a very fast onset of action and a short duration of effect, which presents a challenge to determine a suitable administration regimen with appropriate dosage and frequency of administration of DMT to provide effective therapy for neurological diseases and conditions. This is especially true for neurological diseases and conditions which would benefit from the presence of therapeutic blood levels of DMT over a more extended period of time following administration than can be achieved with a single dose of DMT via injection or inhalation.
- U.S. Publication 2021/0015738. to La Rosa et al. entitled “Oral Dissolvable Film Containing Psychedelic Compound” discloses an oral dissolvable film with DMT to treat neurological conditions.
- the oral dissolvable film that includes: (a) plasticizer, (b) solvent, (c) sweetener, (d) flavoring agent, (e) binder, (f) coloring agent, (g) preservative, and (h) psychedelic compound selected from the group consisting of psilocybin, psilocin, baeocystin, mescaline. LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA. MDEA, MDA, and combinations thereof.
- U.S. Publication No. 2021/0322306, to Espinoza, entitled “Oral Dissolvable Film With High Load of Polymeric Binder” discloses a composition comprising (a) a film matrix that includes one or more binders, wherein at least one binder is a polymeric binder having a glass transition temperature (Tg) of at least 45° C .; (b) solvent: (c) an active pharmaceutical ingredient (API); and (d) pharmaceutically acceptable excipient that includes at least one of a mucoadhesive polymer, plasticizer, filler, bulking agent, saliva stimulating agent, stabilizing and thickening agent, gelling agent, flavoring agent, taste masking agent, coloring agent, pigment, lubricant, release modifier, adjuvant, sweetening agent, solubilizer & emulsifier, fragrance, emulsifier, surfactant, pH adjusting agent, buffering agent, lipid, glidant, stabilizer, antioxidant, anti-tacking agent, hum
- the present disclosure provides, in one respect, a pharmaceutical composition, comprising an amorphous DMT or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier.
- the amorphous DMT may be characterized by a powder x-ray diffractogram free of any discernable peaks and differential scanning calorimetry (DSC) spectra for absence of sharp melting endotherm of crystalline DMT and/or indication of phase change (e.g., glass transition temperature). Stability may be characterized by observing these features over time. particularly after accelerated aging.
- the present inventors have unexpectedly found that DMT may be stabilized in an amorphous form within a polymeric carrier that is suitable for controlled transmucosal release of DMT.
- the stable amorphous DMT compositions may be provided in a form suitable for therapeutic transmucosal administration, e.g., buccal, or sublingual films.
- the carrier may be a mucoadhesive polymer matrix.
- the carrier matrix may comprise a cellulose derivative, a polyacrylic acid, a polyacrylate, a polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, poly(vinyl pyrrolidone-co-vinyl acetate), hydroxypropyl cellulose, hydroxypropyl methyl cellulose, propylene glycol alginate ester, tragacanth, alginate, a gum, a soluble starch, gelatin, lectin, pectin, or chitosan, or a mixture thereof.
- the composition may include a permeation enhancer, a buffering agent, and a saliva stimulating agent.
- the permeation enhancer may include a bile salt, cctvlpyridinium chloride (CPC), sodium laur l sulfate (SLS). Tween 80, L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, propylene glycol, dipropylene glycol, or ethanol, or a mixture thereof.
- the buffering agent may be citric acid, tartaric acid, fumaric acid, sodium citrate, sodium tartrate, or sodium fumarate, or a mixture thereof.
- the saliva stimulating agent may be citric acid, malic acid, lactic acid, ascorbic acid or tartaric acid, or a mixture thereof
- the pharmaceutical composition may also include a stability enhancer, wherein the stability enhancer is an antioxidant or chelator.
- the stability enhancer may be a-tocopherol, tocopherol acetate, L-Glutahione, L-cysteine, ascorbic acid, ascorbyl palmitate, propyl gallate, butylated liydroxvtoluene (BHT). butylated hydroxyanisole (BHA), Tocobiol or Ethylenediaminetetraacetic acid (EDTA), or a mixture thereof.
- composition may further comprise about 0% to about 10%, or about 0.1% to about 10% by weight of the buffering agent, about 2% to about 9% by weight of the buffering agent, or about 3% to about 8.5% by weight of the buffering agent.
- composition may further comprise about 0.1% to about 5% by weight of an antioxidant.
- composition may further comprise about 0% to about 8%, or about 0.1% to about 8% by weight of a saliva-stimulating agent.
- the pharmaceutical composition may further include hydrophilic adjuvants, 'additives or matrix solubilizing agent to promote water ingress and impacts film disintegration. It may include cellulose derivative, starch derivatives, cross linked povidone, cross linked cellulose, cross linked starch or alginates, sucrose, maltose, maltodextrin, isomaltose, ascorbic acids, acids, acid salts, sugar alcohols or a mixture thereof.
- composition may further comprise about 0% to about 15% by weight of a hydrophilic adjuvants/additives or matrix solubilizing agent.
- the pharmaceutical composition may further include a plasticizer, wherein the plasticizer is a polyethylene glycol (PEG), propylene glycol, glycerol, triacetin, or castor oil, or a mixture thereof.
- the plasticizer is a polyethylene glycol (PEG), propylene glycol, glycerol, triacetin, or castor oil, or a mixture thereof.
- the phannaceutical composition may further include a natural and/or artificial sweetener and/or flavoring agent.
- the sweetener may include sucrose, dextrose, fructose, glucose, maltose, maltitol. saccharin, sucralose, neotame, cyclamate, aspartame or acesulfame-K. or a mixture thereof.
- the flavoring agent comprises natural and / or synthetic flavor oils, oleoresins, and extract obtained from multiple parts of the plants such as leaves, fruits, flowers etc.
- the flavoring agent may include peppermint oil. cinnamon oil, vanilla extract, menthol, L-menthol or a mixture thereof.
- composition may further comprise about 0% to about 10% by weight of a sweetener.
- composition may further comprise about 0% to about 5% by weight of a flavoring agent.
- the pharmaceutical composition may further include natural colors such as cochineal dye, carotene, annatto dye. caramel dye etc. or synthetic coloring agents such as D&C and FD&C red. yellow, green, blue, inorganic/mineral colors (iron oxide red, iron oxide yellow, titanium dioxide etc.)
- natural colors such as cochineal dye, carotene, annatto dye. caramel dye etc.
- synthetic coloring agents such as D&C and FD&C red. yellow, green, blue, inorganic/mineral colors (iron oxide red, iron oxide yellow, titanium dioxide etc.)
- the coloring agent is used alone or in combination.
- composition may further comprise about 0% to about 5% by weight of a coloring agent / color.
- the carrier may include hydroxypropyl cellulose, a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate, and hydroxypropylmethylcellulose.
- the carrier may further comprise polyethylene glycol, L-glutathione, citric acid, sucralose, maltitol, and L- menthol.
- the pharmaceutical composition may comprise (1) about 0.5 % to about 60 % by weight of an amorphous N-N-dimcthyltryptaminc or a pharmaceutically acceptable salt or prodrug thereof; (2) about 15% to about 80% by weight of a mucoadhesive polymer matrix; and (3) about 0.1% to about 30% by weight of a permeation enhancer.
- the composition may comprise about 20% to about 35% by weight of the N-N-dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof.
- the composition may comprise about 50% to about 60% by weight of the mucoadhesive polymer matrix.
- the composition may comprise about 0.5% to about 20% by weight of the plasticizer.
- the composition may comprise about 0.5% to about 5% by weight of the plasticizer.
- the composition may comprise, for example, a mucoadhesive polymer matrix that comprises hydroxypropyl cellulose, a copolymer of N-vinyl-2- pyrrolidone and vinyl acetate, and hydroxypropyl methylcellulose.
- the pharmaceutical composition may comprise N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof that is capable of being substantially fully solubilized and released in less than 1 minute following administration of the composition to a patient in need thereof.
- the pharmaceutical composition may comprise N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrag thereof that is capable of being substantially fully solubilized and released in greater than 1 minute and less than 20 minutes following administration of the composition to a patient in need thereof.
- the pharmaceutical composition may comprise N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrag thereof that is capable of being substantially fully solubilized and released in greater than 20 minutes and less than 3 hours following administration of the composition to a patient in need thereof.
- the composition is an oral fdm.
- the oral film may have a film thickness that is about 0.05 mm to about 0.4 mm.
- the invention relates to a method of treating a mental health condition or disorder, comprising administering a therapeutically effective amount of a composition above, wherein the mental health condition or disorder is major depressive disorder.
- the invention relates to a method of making a pharmaceutical composition, comprising the steps of: (1) combining N-N-dimetliyltn piamine or a pharmaceutically acceptable salt or prodrag thereof, and excipients in a solvent; (2) removing the solvent to provide a polymeric matrix comprising an amorphous N-N-dimethyltryptaniine or a pharmaceutically acceptable salt or prodrag thereof.
- the solvent may comprise methanol or an organic solvent in water, which may for example include a methanol-water in a 0:100 or 100:0 ratio.
- the method may comprise casting the polymeric matrix by removing the solvent.
- the solvent may include any organic solvent with a boiling point lower than water.
- FIG. 1 shows permeability of DMT formulations (1) citric acid / citrate and (2) methanol/water through prepared films of porcine buccal mucosa.
- FIG. 2 shows a PXRD Spectra of DMT polymeric film Formulation 23 showing the presence of crystalline peaks indicative of DMT.
- FIG. 3 A shows PXRD Spectra of DMT polymeric film Formulation 22 showing the absence of crystalline peaks, including any peaks indicative of DMT.
- FIG. 3B shows PXRD Spectra of DMT polymeric film Formulation 24 showing the absence of crystalline peaks, including any peaks indicative of DMT.
- FIG. 4A shows disintegration test for Formulations 22 and 23.
- FIG. 4B shows disintegration test for Formulation 24.
- FIG. 5 is a chart showing the dissolution profile for 40 mg DMT films in 500 mL buffer at pH 6 for formulations 22. 23. and 24.
- FIG. 8 shows DSC Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4)
- FIG. 9 shows PXRD Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4)
- FIG. 10A shows DSC Spectra of DMT polymeric film (Lot # RD-2021 Dec-01P4) 6 Month 25C/60% relative humidity.
- FIG. 10B shows DSC Spectra of DMT polymeric film (Lot # RD-2021 Dec-01P4) 6 Month 40C/75% relative humidity.
- FIG. 11A shows PXRD Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4) 6 Month 25C/60% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
- FIG. 1 IB shows PXRD Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4) 6 Month 40C/75% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
- FIG. 13 A shows the study design for in-vitro tolerability of prepared buccal film evaluated using the EpiOral in vitro tissue model and evaluating cell viability using MTT assay.
- FIG. 13B shows the results of cell viability testing after dosing according to the study design shown in FIG. 13 A.
- the present invention relates to compositions of amorphous DMT which are capable of stabilizing DMT in amorphous form and providing controlled release of DMT in a suitable dosage form, for example, a transmucosal dosage form.
- the invention also relates to methods of making these amorphous DMT compositions, and methods of treatment of disease and disorders, e.g., neurological disorders, by administering these compositions to patients in need thereof.
- a pharmaceutically acceptable carrier may include a plurality of pharmaceutically 7 acceptable carriers, including mixtures thereof.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered and includes, but is not limited to, such liquids and powders that are hydrophilic substances, hydrophobic substances and substances that possess both hydrophilic and hydrophobic properties such as emulsifiers.
- the term “device,” as used herein, refers to an apparatus or system capable of delivering a drug to a patient in need thereof.
- administer refers to administering a compound or pharmaceutically acceptable salt of the compound or a composition or formulation comprising the compound or pharmaceutically acceptable salt of the compound to a patient.
- in need of treatment and the term “in need thereof’ when referring to treatment are used interchangeably and refer to a judgment made by a caregiver (e.g., physician, muse, muse practitioner) that a patient will benefit from treatment.
- a caregiver e.g., physician, muse, muse practitioner
- treat and “treatment” refer herein to therapeutic treatment, including prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change associated with a disease or condition.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of the extent of a disease or condition, stabilization of a disease or condition (i.e.. where the disease or condition does not worsen), delay or slowing of the progression of a disease or condition, amelioration or palliation of the disease or condition, and remission (whether partial or total) of the disease or condition.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- Treatment can, when concerning depression, also include reducing at least one sign or symptom of depression.
- Examples of a sign or symptom of depression include depressed mood, diminished interest in activities, weight loss or gain, decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to concentrate or indecisiveness, or suicidal ideation or behavior.
- pharmaceutically acceptable refers to a component of a pharmaceutical composition that is compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
- an effective amount refers to the amount of active agent that elicits the biological or medicinal response in a tissue, system, or individual that is being sought by a researcher, healthcare provider or individual.
- neuropsychiatric disorder such as depression (including severe depression such as treatment-resistant depression, major depressive disorder and persistent depressive disorder), catatonic depression, a depressive disorder due to a medical condition, postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder, anxiety, anxiety disorder, social anxiety disorder, general anxiety disorder (GAD), avolition disorder, bipolar disorder (including bipolar I disorder and bipolar II disorder), post-traumatic stress disorder, body dysmorphic disorder, abnormalities of mood or emotion, including the above conditions, dysthymia, schizoaffective disorder, schizophrenia and other psychotic disorders, panic disorder, traumatic stress disorders, phobic disorders, and personality disorders with abnormal mood, such as borderline personality disorder, schizoid and schizotypal disorders and suicide ideation, or rumination/unproductive repetitive thoughts negatively impacting one’s behavior/mood/ability to focus, obses
- a neuropsychiatric disorder such as depression (including severe depression such as treatment-resistant depression, major depressive disorder and persistent
- treatment-resistant depression means a depressive disorder which does not respond satisfactorily to adequate treatment.
- TRD is a complex phenomenon influenced by variety in depressive subtypes, psychiatric comorbidity, and coexisting medical illnesses. Although TRD episodes are most commonly associated with major depressive disorder (MDD), they are also seen in the depressed phase of bipolar disorder.
- MDD major depressive disorder
- onset means the time to achieve maximum blood plasma concentration following administration (i.c., Tmax) and may also be described as “onset of action”.
- Tmax maximum blood plasma concentration following administration
- a “rapid onset” in the context of the present disclosure means that the drug achieves Cmax within about 20 minutes (e g., within about 2-10 minutes).
- onset following administration of a composition according to the present disclosure is less rapid, and consequently less “harsh” to the patient, than if DMT is administered by IV injection.
- Tmax may be between 10 minutes and 90 minutes.
- the term “offset” means the time betw een the last time the concentration of DMT is at Cmax ⁇ 10% and the first time the plasma concentration of DMT reduces to a threshold level below which the drug no longer has any meaningful therapeutic effect (c.g., about 250 nmol/L or 47.07 ng/mL).
- a “rapid offset” in the context of the present disclosure means less than about 10 minutes. However, although rapid, the offset is still sufficiently long for the drug to exert a reasonable duration of psychedelic effects.
- uccal delivery or “buccal administration” refers to a route of administration in which the pharmaceutical dosage form is applied between the patient’s cheek and gum (i.e., the buccal cavity).
- sublingual deliver ⁇ refers to a route of administration in which the pharmaceutical dosage form is applied under the patient’s tongue.
- N, N-Dimethyltryptamine includes the compound of formula (I):
- DMT free form or “DMT free base” refers to the compound of formula (I) without a pharmaceutically acceptable salt.
- compositions as used herein with reference to “DMT or a pharmaceutically acceptable salt thereof’ means a pharmaceutically acceptable acid addition salt.
- acidic reagents may be used to prepare salts, in particular pharmaceutically acceptable salts, of DMT.
- suitable acidic reagents include fumaric acid, hydrochloric acid, tartaric acid, citric acid, hydrobromic acid, sulfuric acid, succinic acid, phosphoric acid, acetic acid, maleic acid, lactic acid, tartaric acid and gluconic acid.
- the form of the DMT salt in a pharmaceutical composition of the present disclosure or otherw ise used according to the various aspects of the present disclosure, and embodiments thereof, is a pharmaceutically acceptable salt of a fumarate, hydrochloride, tartrate, succinate, or citrate salt, e.g., a fumarate salt.
- Amorphous refers to a solid that is lacking the three- dimensional long-range order of a crystalline material, possess a more random arrangement of molecules, and have physical properties such as its solubility etc., quite different from those of their corresponding crystalline states.
- microenviromental pH also called “local pH” also called “surface pH” refers to the pH of the region of the carrier/polymeric matrix immediately surrounding the active agent as the matrix hydrates and/or dissolves, for example, in the mouth of the user. Buffering agent also influences the disintegration time of buccal film.
- transmucosal film refers to polymeric film capable of embedding active ingredients which allows mucosal adhesion, complete solubilization or dissolution, diffusion and transmucosal delivery' of active for systemic absorption.
- Transmucosal refers to any route of administration across the mucosal membrane. Examples include, but are not limited to, buccal, sublingual, gingival, on the tongue, nasal, vaginal, and rectal. In this embodiment, the administration route is buccal or sublingual.
- Mucoadhesion refers to the phenomenon where polymers hydrates in presence of mucous fluid and adhere to the mucosal surface. Polymers that can readily form a gel in an aqueous environment can cause dehydration at the mucosal site of application. The water drawn into the film will help dissolving the active ingredient. Once the active ingredient is absorbed more water is absorbed by the remaining film due to a concentration gradient. This process leads to the mixture of formulation and mucus and can thus increase contact time with the mucous membrane.
- Polymeric carrier matrix or mucoadhesive polymeric matrix refers to a carrier comprising combination of polymers with different functional properties such as but not limited to mucoadhesion, stabilizing (chemical and physical stabilizer), gelling, film forming, release controlling, swelling etc.
- the present invention in one aspect involves oral transmucosal formulations in which an active ingredient comprising DMT is released in a therapeutically effective manner.
- DMT is a natural occurring molecule and is a known psychedelic drug with rapid onset and relatively short duration effect. DMT is not active upon oral administration and converts to inactive metabolites in gastrointestinal tract (GI) and liver before sufficient penetration to the brain can occur which results in low oral bioavailability.
- alternate route of administration such as oral transmucosal (e.g., buccal /sublingual / gingival /mucosal (on the oral mucosa) or on the tongue is explored to improve DMT bioavailability by circumventing GI and hepatic first pass metabolism. See Metabolism GAP Analysis of DMT Literature. Gina Patel, Mpharm, PhD. President and CEO, Patel Kwan Consultancy, 25th August 2020.
- DMT is believed to have good permeability across the biological membrane.
- DMT free form exhibited poor aqueous solubility and hence, from a buccal formulation permeability of DMT could be governed by the solubility of DMT at buccal mucosa.
- solubility enhancement of DMT at the site of absorption at buccal mucosa is required to achieve its bioavailability.
- Several approaches can be employed for solubility enhancement of DMT at buccal site such as employing, but not limited to. modifying physical form, salt, prodrug form of DMT, modification of microenvironmental pH, solubilizer, micronization. nanoparticles. emulsions etc.
- buccal formulations are design with an objective to modify polymorphic form / solid state form, preferably to amorphous form, to improve its solubility and thus the overall permeability across the buccal mucosa to achieve desired pharmacokinetics.
- DMT free base is a lipophilic molecule (logP - 2.573) with a small backbone (Mol wt. 188.27 g/mol).
- the present inventors found that DMT may exist in several polymorph forms, including at least forms I-IV, with form IV of DMT being most stable among different forms studied.
- the present inventors also found that amorphous N,N-DMT exhibited a low glass transition temperature (-18 °C) and readily cry stallizes, particularly at temperatures above the Tg. For this reason, DMT is expected to have insufficient stability to be reliably delivered to the patient in amorphous form without a stabilizer.
- the present inventors have discovered that by controlling the conditions upon which DMT is incorporated into a polymeric film, it is possible to obtain a film that includes DMT in a stable amorphous form suitable for transmucosal administration.
- the conditions to achieve a stable DMT -containing film may include use of particular solvents in particular amounts alone or in combination with modifying the pH of the composition. These conditions may be provided to solubilized DMT within a casting solution whereby the casting solution is molded into a suitable form, and evaporation of solvent leads to the creation of the polymeric film.
- the process may include spray drying tire polymer or stabilizer and DMT in a suitable solvent in order to incorporate DMT in a stable amorphous form.
- the resultant spray dried material may be directly incorporated into a polymeric film, or tablets or other suitable dosage forms.
- compositions and dosage forms including but not limited to, fast dissolving tablets, microporous hollow fibers, chewing gum, tablets, fast or rapid disintegrating tablets, wafers, disks, powders, mucoadhesive gels, ointments, pastes, sponges, emulsions, single layer film, bilayer film, multilay ered film, mouthwashes, aerosols, spray s, drops, gummies, bi-layer or multi-layer tablets, mucoadhesive tablets etc.
- preferred formulation is a buccal/subinguinal film. These films may be divided in three main categories depending on the time for dissolution in the oral cavity.
- Quick Release (QR) film which solubilizes within seconds, generally less than a minute, other is moderate releasing film, which takes a few minutes to up to 20 minutes, and sustained release (SR) film, which solubilizes at a slower rate than moderate releasing film and takes more than 20min to up to few hours.
- QR Quick Release
- SR sustained release
- QR films release active in the oral cavity in seconds and offer less or no contact time with buccal or sublingual mucosa.
- moderate release or SR films offer longer contact time at the mucosal surface which increases the chance of the active ingredient to be directly absorbed through mucosa.
- Phannaccutical compositions comprising amorphous DMT or a pharmaceutically acceptable salt thereof suitable for buccal and sublingual administration include rapidly dissolving tablets, wafers, films, strips or patches, orodispersible tablets, oral gels, medicated lollipops, sprays, drops, gummies and other formulations that are retained on the buccal or sublingual mucosal surface.
- the examples of buccal / sublingual films include a rapid/quick release film (simply QR film) and moderate release composition comprising the drug present as a solid solution or a suspension form or a partially soluble form in a mucoadhesive polymeric carrier matrix, where upon administration of film in the oral cavity, the film disintegrates in a specified time to release drug and make it available for absorption through oral mucosa.
- QR films and moderate release fihns are designed to provide instantaneous release of the active ingredient after administration.
- an amorphous DMT / polymer composition that includes one or more of matrix polymer or mucoadhesive polymer, permeation enhancer, plasticizer, antioxidant, buffering agent, and optionally sweetening agent, saliva stimulating agent, coloring agent, hydrophilic adjuvant / additive and/or flavoring agent.
- Suitable mucoadhesive polymers include one or more polymers selected from cellulose derivatives, polyacrylic acids, polyacrylates, polyethylene oxides, polyvinyl pyrrolidones, poly(vinyl pyrrolidone-co-vinyl acetate), polyvinyl alcohols, propylene glycol alginate esters, tragacanth, alginates, gum (including karaya gum, guar gum, xanthan gum), soluble starch, gelatin, lectin, pectin, and chitosan.
- the mucoadhesive polymer comprises one or more polymers selected from a hydrophilic polymer, a polysaccharide and its derivatives, and a hydrogel.
- the mucoadhesive polymer comprises one or more polymers selected from polyacrylic acids, polyacrylates, celluloses, e.g., carboxycelluloses (e.g., sodium carboxymethyl cellulose), hydroxyalkyl cellulose (e.g., hydroxypropylcellulose, hydroxyethylcellulose and hydroxyethyl ethyl cellulose), polyvinylpyrrolidone, poly(vinyl pyrrolidonc-co-vinyl acetate) and polyvinyl alcohol.
- the mucoadhesive polymer comprises one or more polymers selected from Carbopol (poly acry lic acid), carboxymethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and gum.
- the mucoadliesion is attributed to material containing thiol group such as but not limited to, N-acetyl cysteine, glutathione, thiolated polycarbophil (a copolymer of acrylic acid and divinyl glycol), thiolated chitosan, thiolated sodium carboxymethylcellulose, thiolated sodium alginate, thiolated sodium hydroxypropyl cellulose, thiolated hyaluronic acid and thiolated pectin.
- thiol group such as but not limited to, N-acetyl cysteine, glutathione, thiolated polycarbophil (a copolymer of acrylic acid and divinyl glycol), thiolated chitosan, thiolated sodium carboxymethylcellulose, thiolated sodium alginate, thiolated sodium hydroxypropyl cellulose, thiolated hyaluronic acid and thiolated pectin.
- the mucoadhesive polymer is water- swellable.
- the mucoadhesive polymer is present alone or in combination in a total amount of about 15% to about 80% by weight of the film composition.
- the film compositions can further include a permeation enhancer.
- the film composition comprises a permeation enhancer, e.g., comprising one or more permeation enhancers selected from bile salts such as sodium deoxycholate (SDC), including sodium glycodeoxycholate (SGDC), sodium taurodeoxycholate (STDC) and others; synthetic surfactants such as Cetylpyridinium chloride (CPC), Sodium lauryl sulfate (SLS) Tween 80 and others but not limited to L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, propylene glycol, dipropylene glycol, ethanol, and surfactants.
- the permeation enhancer is present in an amount of about 0.1% to about 30% by weight of the film composition.
- the film composition can further include an antioxidant, e.g., comprising one or more antioxidants such as a-tocopherol, tocopherol acetate, L-Glutahione, L cysteine, ascorbic acid, ascorbyl palmitate, propyl gallate, butylated hydroxy toluene (BHT), butylatcd hydroxy anisole (BHA). Tocobiol and Ethylenediaminetetraacetic acid (EDTA).
- the antioxidant is present in an amount of about 0.1% to about 5% by weight of the film composition.
- the film compositions can further include plasticizer.
- a plasticizer improves the flexibility of the film and reduces the brittleness of the film by reducing the glass transition temperature of the film.
- the film composition comprises plasticizer e.g., comprising one or more plasticizers selected from but not limited to polyethylene glycols (PEGs) such as PEG 300. PEG 400 etc.; propylene glycol, glycerol, triacetin, castor oil.
- the plasticizer is present in an amount of about 0.5% to about 20% by weight of the film composition.
- the film compositions can further include sweetening agent to improve the taste.
- the film composition comprises sweetener e.g., comprising one or more selected from but not limited to sucrose, dextrose, fructose, glucose, liquid glucose, maltose, maltitol. saccharin, sucralose, neotame, cyclamate, aspartame and acesulfame-K etc.
- the sweetner is present in an amount of about 0% to about 10% by weight of the film composition.
- the film compositions can further include a saliva stimulating agent.
- a saliva stimulating agent In some of the examples, citric acid, malic acid, lactic acid, ascorbic acid, succinic acid, fumaric acid and tartaric acid are used as salivary stimulants. Stimulating agents are used alone or in combination between about 0% to about 8% or about 0.1 to about 8% w/w of weight of the dry film composition.
- the film composition can further include a flavoring agent.
- a flavoring agent In some examples natural and / or synthetic flavor oils, oleoresins, and extract obtained from multiple parts of the plants such as leaves, fruits, flowers etc. such as peppermint oil, cinnamon oil, vanilla extract, menthol. L- menthol or a mixture thereof are used as flavoring agent.
- the flavoring agent is present in an amount of about 0% to about 5% by weight of the film composition.
- the film composition can further include hydrophilic adjuvants/additives or matrix solubilizing agent to promote water ingress and impacts film disintegration.
- hydrophilic adjuvants/additives or matrix solubilizing agent to promote water ingress and impacts film disintegration.
- cellulose derivative, starch derivatives, cross linked povidone, cross linked cellulose, cross linked starch or alginates, sucrose, maltose, maltodextrin, isomaltose, ascorbic acids, acids, acid salts, sugar alcohols or a mixture thereof are used as hydrophilic adjuvants/additives or matrix solubilizing agent.
- the hydrophilic adjuvants/additives or matrix solubilizing agent is present in an amount of about 0% to about 15% by weight of the film composition.
- the film composition can further include include natural colors such as cochineal dye, carotene, annatto dye, caramel dye etc. or synthetic coloring agents such as D&C and FD&C red. yellow, green, blue, inorganic/mineral colors (iron oxide red, iron oxide yellow, titanium dioxide etc.)
- the coloring agent is used alone or in combination. In some embodiments, the coloring agent is present in an amount of about 0% to about 5% by weight of the film composition.
- DMT is weak base with pKa of 8.86.
- the pH of the film plays a very important role in balancing its ionized vs unionized form at the site.
- microenvironmental pH is maintained to achieve balance between ionized and unionized form and thus the permeation across the mucosa.
- the polymeric film surface pH / diffusion environment also called microenvironmental pH, may be maintained to desired pH close to physiological pH of saliva.
- the microenvironmental pH can be adjusted and /or maintained by adjusting polymeric film pH utilizing methods including, but not limited to, the use of acid, base, buffering agent in die formulation.
- the film composition can include acid, base or buffering agent which could influence the pH and help maintain desired microenviromental pH at the site of application in the oral cavity.
- the film composition comprises of acid, base or buffering agent, not limited to, citric acid, tartaric acid, fumaric acid, sodiimi citrate, sodium, tartrate, sodium fumarate etc. Buffering agent are used alone or in combination bet een about 0% to about 10% or about 0.1 to about 10 % w/w of the film composition.
- a inactive backing layer may be added on top of the active film to make it bilayer film in order to reduce or prevent erosion from the back side of the film when applied to the mucosal surface.
- Backing layer may furher help to improve taste of the film.
- the amount of active e.g., DMT or its suitable form, to be incorporated into the polymeric fdm depends on the desired dosage to be administered.
- DMT or its suitable form can be present in about 0.5 % to about 60 % by weight of film.
- buccal or sublingual film One additional benefit of buccal or sublingual film is that less dose is required to achieve desired bioavailability in contrast to an oral dose which needs co-administration of monoamine oxidase inhibitors to achieve DMT oral bioavailability. See, e.g.. N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past. Present, and Future Research to Determine Its Role and Function. Steven A. Barker, Front. Neurosci.. 06 August 2018 https://doi.org/10.3389/fnins.2018.00536.
- DMT N-Dimethyltryptamine
- buccal or sublingual films were prepared with a thickness range from about 0.01 mm to about 1.5 mm, and more specifically from about 0.05 to about 0.4 mm. Further, the thickness of the film could be varied from 10 % to 90 % to these ranges based on the drug-polymeric mixture.
- the prepared films were evaluated for physicochemical properties such as appearance, disintegration time, dissolution, assay, water content, degradation products, polymorphic form evaluation, mechanical properties such as folding endurance, elongation, tensile strength etc. and ex-vivo permeability through porcine buccal mucosa or permeapad membrane.
- the present work also aims to convert API to its amorphous form to improve solubility and maintaining same form in the fonnulation throughout the shelf life.
- Suitable methods of manufacturing has been chosen to convert DMT into amorphous form and various combinations of polymers have been incorporated in the formulation to stabilize the amorphous fonn in the film during the shelf life.
- the choice of polymers includes one or more polymers selected from cellulose derivatives, polyacrylic acids, polyacrylates, polyethylene oxides, poly vinyl pyrrolidones, poly(vinyl pyrrolidone-co-vinyl acetate), polyvinyl alcohols, propylene glycol alginate esters, tragacanth, alginates, gum (including karaya gum, guar gum, xanthan gum), soluble starch, gelatin, lectin, pectin, and chitosan.
- the polymer comprises one or more polymers selected from a hydrophilic polymer, a polysaccharide and its derivatives, and a hydrogel.
- the polymer comprises one or more polymers selected from polyacrylic acids, polyacrylates, celluloses, e.g., carboxycelluloses (e.g.. sodium carboxymethyl cellulose), hydroxyalkyl cellulose (e.g., hydroxypropylcellulose, hydroxyethylcellulose and hydroxyethyl ethyl cellulose), polyvinylpyrrolidone, and polyvinyl alcohol.
- the polymer comprises one or more polymers selected from Carbopol (polyacrylic acid), carboxymethyl cellulose, carboxyethyl cellulose, hydroxy propyl cellulose, hydroxypropylmethyl cellulose, and gum.
- DMT has been shown to be highly prone to oxidation upon force degradation study as suggested by the data in the above table. It is important to incorporate antioxidant(s) in the formulation to prevent oxidation of DMT during the shelf life and to form stable films.
- Different manufacturing techniques such as solvent casting method, hot-melt extrusion, semisolid casting, solid dispersion extrusion, rolling method etc. can be used for DMT polymer formation, for example in the preparation of transmucosal (e.g., buccal, sublingual etc.) film manufacturing.
- the solvent casting method is the most preferred method for the manufacturing of buccal film and has been well studied in the past.
- the buccal film of DMT is manufactured using the solvent casting method.
- DMT as Form I (Investigations into the polymorphic properties of N.N-dimethyltryptamine by X-ray diffraction and differential scanning calorimetry, Gaujac et al (2013)) or Form IV and excipients are mixed with suitable solvent system to form a uniform mixture with DMT in solution form.
- the resulting mixture is subjected to deaeration, used to cast a film, allowed to dry to obtain films containing DMT as amorphous form.
- the films are then cut into strips of desired sizes to produce desired film strengths of DMT.
- the solvents have been selected to solubilize DMT completely in the mixture and upon casting and dry ing to evaporate solvent/s to form amorphous DMT in the polymer matrix.
- the well-known techniques like PXRD and DSC have been utilized to confirm the conversion to the amorphous form.
- DMT alone and films containing DMT as amorphous and/or crystalline form have been prepared in combination with other excipients to achieve solubility and permeability.
- Example 1 DMT alone and films containing DMT as amorphous and/or crystalline form have been prepared in combination with other excipients to achieve solubility and permeability.
- DMT polymeric films were prepared according to the formula given in table 4 below.
- the film using the above composition was prepared as follows: DMT and excipients were mixed with either water-based citrate buffer or methanol - water (70:30) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a deaerated mixture, dried and cut into strips. [0121] Further, permeability of DMT through prepared films were evaluated using ex-vivo permeation study i.e., using porcine buccal mucosa as presented below.
- Ex-vivo permeation is well studied using Franz diffusion cell or Using chambers utilizing animal mucosa (e.g., Pig or sheep buccal mucosa) or by using commercially available synthetic membranes (e.g., Permeapad®).
- the Franz diffusion cell consists of two compartments; one is the donor compartment, the other is the receptor compartment of 18 mL capacity and having 0.785 cm 2 effective diffusion area. The temperature is maintained at 37°C by water jacket. This technique can also establish good discrimination tool to optimize formulation composition to achieve desired permeability and determine time required for film to be retained at the buccal surface to offer desired rate and extent of DMT absorption.
- Films prepared using aqueous as well as hydroalcoholic mixture demonstrated permeability of DMT across the porcine buccal mucosa as shown in FIG. 1
- DMT polymeric film formation were evaluated using different matrix forming polymers or combination thereof, according to the formula given in
- the film using the above composition was prepared as follows: DMT and excipients are mixed with methanol - water (70:30) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a de-aerated ix lure, dried and cut into strips.
- DMT observed to be extensively degrade under oxidative stress.
- antioxidant(s) I Chelating agent were incorporated in the buccal / sublingual film to stabilize DMT. Films were prepared using different antioxidant using solvent casting method as0 described in example 2 having the compositions shown in Table 6 below.
- antioxidants were found to improve stability of DMT in polymeric films.
- Example 4 Further, stability of DMT was studied at various levels of L-glutathione. Thus, DMT films were prepared using solvent casting method and evaluated for stability utilizing HPLC method as described in Table 8 below.
- DMT polymer films were prepared using different solvent composition with and without citric acid according to the formula given in the table 10 below.
- the DMT films using the above composition were prepared as follows: DMT and excipients are mixed with either water (100 %) or methanol - water (50:50) solvent mix to form a homogenous mixture also called blend. The resulted mixture was de-aerated. The film was casted using a de-aerated mixture, dried and cut into strips. The films were characterized for DMT form using PXRD as presented shown in FIGs. 2 and 3A-3B.
- FIG. 2 shows the PXRD Spectra of DMT polymer film Formulation 23 (Crystalline Peaks of DMT-Present).
- FIG. 3 A shows the PXRD Spectra of polymer film Formulation 22 (Crystalline Peaks of DMT-Absent).
- FIG. 2 shows the PXRD Spectra of DMT polymer film Formulation 23 (Crystalline Peaks of DMT-Present).
- FIG. 3 A shows the PXRD Spectra of polymer film Formulation 22 (Crystalline Peaks of DMT-
- 3B shows the PXRD Spectra of polymer film Formulation 24 (Crystalline Peaks of DMT-Absent).
- DMT is present in amorphous form in formulation 22 and 24.
- DMT was present completely in a solution form in the blend resulting in a film with amorphous DMT.
- DMT was completely solubilized in the blend despite excluding of methanol, principally due to the presence of citric acid which helps DMT to completely solubilize in 100 % water phase by lowering the blend pH and finally yielded a film with amorphous DMT.
- DMT active pharmaceutical ingredient API
- the formulation 23 exhibited permeation comparable to the DMT API. For example, at around 180 minutes formulation 23 exhibited approximately 29% while the DMT API exhibited about 33% release as shown in FIG. 6.
- DMT exhibited permeability through pig buccal mucosa for films with amorphous DMT (Formulation 22 & 24), crystalline DMT (Formulation 23) and DMT dispersion in PBS pH 7.0.
- permeability of DMT fdm (Formulation 23) and DMT dispersion in PBS pH 7.0 was found to be higher as compared to the Formulation 22 and 24 fdm which could be attributed to pH of the donor chamber media.
- Formulation 23 and DMT dispersion in PBS exhibited pH of 8.9 and 9.5 respectively which is close to the pKa of DMT 8.68 and thus it is believed that for formulation 23 and DMT dispersion more unionized DMT could be present in the donor chamber resulting in higher permeability' than formulation 22 and 24 fdms which exhibited pH of 7.6 and 7.8 respectively where more ionized DMT could be present.
- DMT polymer films were prepared according to the formula given in the table below.
- the films were prepared with different levels of citric acid to produce pH in the range of pH 5 to 10 and the effect of pH was evaluated for permeability as shown m Table 11.
- the DMT films using the above composition were prepared as follows: DMT and excipients are mixed with methanol - water (70:30) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a de-aerated mixture, dried and cut into strips. The films were measured for surface pH and data presented in above composition table.
- permeability of DMT through prepared films were evaluated using ex-vivo permeation study i.e., porcine buccal mucosa or Permeapad® as presented below.
- the Permeapad® (Certificate No. 014557268) is the barrier consist of support layer and lipid layer.
- the barrier is made up of soy phosphatidylcholine S-100 as the lipid layer.
- a thin layer of lipid is applied to a hydrophilic support sheet (Piltz GmbH, Taunusstein, Germany) in organic solution. The solvent is allowed to evaporate to form the barrier.
- Permeability of the model drug metoprolol was detennined across Penneapad® and compared to literature data for permeation across TR146 cell layers, porcine buccal mucosa ex vivo and in Gottingen minipigs.
- Permeapad® for prediction of buccal absorption: A comparison to in vitro, ex vivo and in vivo method, Hanady Ajine Bibi a, Rene Holm b,l, Annette Bauer-Brandl a,
- DMT polymer film were prepared according to the formula given in table 13 below.
- the buccal/sublingual film using above composition were prepared as follows: DMT and excipients arc mixed with methanol - water (50:50) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a de-aerated mixture and dried until loss on drying (LOD) of the dried film is achieved, preferably within 5 to 11 % w/w to form flexible film sheets. The thickness of the flexible film sheets is preferably within 0.05 - 0.40 mm.
- the prepared film sheets comprise amorphous DMT preferably within 3-7 mg/cm 2 .
- the individual prepared films were cut into strips of varied sizes and/or weight to achieve any strength, including from 2.5mg to 80mg.
- Conversion of DMT to amorphous form is critical for the buccal film formulation to achieve high aqueous solubility to ensure drug solubilization at the mucosal surface in buccal cavity' to facilitate transmucosal permeation of DMT and systemic absorption as shown in FIG. 8.
- the PXRD Spectra of DMT Polymer Film (Lot # RD-2021 DEC-01P4) is shown in FIG. 9. confirming the absence of crystalline peaks, including any peaks associated with DMT.
- amorphous form of DMT has been generated successfully using combination of various polymers. Further, addition of these polymers helps keep stable amorphous form in the film even under accelerated storage condition i.e., room temperature (25°C/60%RH) and even at worst conditions of 40°C/75% RH up to 6M as shown in Figs. 10A- 10B.
- FIG. 10A shows DSC Spectra of Polymer Film (Lot # RD-2021Dec-01P4) 6 Month 40°C/75% relative humidity.
- FIG. 10B shows DSC Spectra of DMT Polymer Film (Lot # RD- 2021Dec-01P4) 6 Month 40°C/75% relative humidity.
- FIG. HA shows the shows PXRD Spectra of DMT Polymer Film (Lot # RD-202 IDec- 01P4) 6 Month 25°C/60% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
- FIG. 1 IB shows PXRD Spectra of DMT Polymer Film (Lot # RD- 2021Dec-01P4) 6 Month 40°C/75% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
- the buccal film was tested for disintegration with 20mL Phosphate Buffer Saline pH 7.0 in Petri dish.
- the film disintegration time was found to be between 3-10 minutes.
- solubility of buccal film and neat API was measured in Phosphate buffer saline pH 6.8 and found to be 24.6mg/mL and 2.3mg/mL respectively. This improved solubility also suggests there was a several fold increase in solubility of DMT in polymeric films compared to its crystalline form.
- the study was performed using positive control with 1.0% Triton X100 and a negative control without dosing the formulation.
- the samples included neat API in acidic and basic solutions along with placebo and formulated DMT films at different time points as shown in above study design.
- amorphous DMT can also be manufactured using spray drying process. Breifly, polymer and/or stabilizer and DMT are mixed in a suitable solvent /s mixture to form a solution followed by spray drying at controlled conditions to form stable amorphous DMT powder. The composition of this polymer is shown in Table 21 below.
- amorphous DMT can be formulated as tablets using direct compression process.
- amprophous DMT can also be formulated as polymeric film, tablets such as fast or rapid disintegrating tablets, rapidly dissolving tablets, orodispersible tabelts, bi-layer or multi-layer tablets, mucoadhesive tablets, etc. or any other suitable dosage form.
- tablets such as fast or rapid disintegrating tablets, rapidly dissolving tablets, orodispersible tabelts, bi-layer or multi-layer tablets, mucoadhesive tablets, etc. or any other suitable dosage form.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Pharmaceutical compositions including an amorphous N-N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.
Description
N-N-DIMETHYL TRYPTAMINE (DMT) AND DMT ANALOG COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF
FIELD OF THE INVENTION
[0001] The present disclosure relates to novel N,N-dimethyltryptamine (hereinafter ‘'DMT”) compositions and methods of treating neurological diseases and conditions. Specifically, the disclosure provides improved pharmaceutical compositions comprising DMT in a form that permits controlled transmucosal release of DMT suitable for treatment of neurological diseases and conditions.
BACKGROUND OF THE INVENTION
[0002] Lysergic acid diethylamide (“LSD”), psilocybin and DMT are serotonergic agents often referred to as “classical hallucinogens” or "psychedelics," and have the ability to induce qualitatively altered states of consciousness, such as euphoria, trance, transcendence of time and space, spiritual experiences, or dissolution of self-boundaries, while other effects such as sedation, narcosis, or excessive stimulation are only minimal. Chemically, serotonergic psychedelics are either phenylalkylamines or indoleamines. with the indoleamine class being divided into two subsets, ergolines and try ptamines.
[0003] Naturally occurring psychedelics, such as the DMT, which is contained in the South American shrub Psychotria viridis, psilocybin, which is contained in over 200 mushroom species, or mescaline, which is contained in the Peyote cactus of the American Southwest and Northern Mexico, have been used for centuries by indigenous cultures in ritualistic or sociocultural contexts, and in the context of religious sacraments. While an unspecific “healing” potential had been ascribed to the use of naturally occurring psychedelics in those settings, more scientific investigations into their potential therapeutic application for defined diseases had not been pursued until after the discovery of the synthetic ergoline lysergic acid diethylamide (“LSD”) in 1943.
[0004] With emerging knowledge about the serotonin system and its role in brain function, researchers began to specify the molecular activity’ of psychedelic drugs. However, how that activity translated into the observed therapeutic effects in mental disorders was less clear. Two main concepts were proposed: The first concept was coined “psycholytic therapy” and it emphasized the ability of psychedelics given at low doses to facilitate the loosening of psychological defensive mechanisms, which in combination with psychotherapy allows a deep introspective insight and the revival of traumata and their subsequent catharsis. The basic mechanism considered in the psycholytic approach was therefore the activation and deepening of
the concomitant psychotherapeutic process, and it required multiple drug and therapy sessions. The second concept was coined as "psychedelic therapy" and it emphasized the ability of psychedelics given at relatively high single doses to induce so called “peak psychedelic experiences.” Peak experiences are predominantly characterized by the loss of judgment to time and space and the dissolution of ego boundaries, which often culmmates in the experience of a blissful state and feelings of being a whole and harmonious existence in the cosmic unity. The basic mechanism considered in the psychedelic approach was therefore to produce a unique, overwhelming experience with an intuitive perception of psychological integration and harmony and subsequent self-improvements and enhanced joy in living and a sense of inner peace.
[0005] Although scientific research around the use of psychedelics for the treatment of mental disorders blossomed in the 1960s, there was also a rapidly growing recreational use of these substances, and soon psychedelics were depicted in the media as highly dangerous drugs of abuse. A perceived danger to the social order led to the passage of the United States Controlled Substances Act of 1970, under which LSD and other psychedelics were placed into the most restrictive category' Schedule 1. which contains drugs deemed to have no medical use and a high potential for abuse. Very little progress was made regarding possible therapeutic uses of psychedelic drugs for the next 30 years.
[0006] Recently, interest in the field of psychedelic therapy has rcsurgcd, and classical psychedelics have shown preclinical and clinical promise in treating psychiatric disorders (Carhart-Harris and Goodwin, The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future, Neuropsychopharmacology; 42, 2105-2113 (2017)). In particular, psilocybin has demonstrated significant improvement in a range of depression and anxiety rating scales in randomized double-blind studies (Griffiths et al., Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized doubleblind trial. Journal of Psychopharmacology 30(12), 1181-1197 (2016)).
[0007] DMT is also understood to hold therapeutic value as a psychedelic, with efficacy trials ongoing to assess the effect of DMT or DMT fumarate administered intravenously to subjects with major depressive disorder (“MDD”). However, although the intrinsic properties of DMT make it an attractive possible medication, especially for neurological diseases and conditions, current therapeutic compositions and modes of administration complicate treatment and may not provide optimal therapeutic results. For example, when smoked or delivered intravenously, DMT has a very fast onset of action and a short duration of effect, which presents a challenge to determine a suitable administration regimen with appropriate dosage and frequency of administration of DMT to provide effective therapy for neurological diseases and conditions. This is especially true for neurological diseases and conditions which would benefit from the presence
of therapeutic blood levels of DMT over a more extended period of time following administration than can be achieved with a single dose of DMT via injection or inhalation.
[0008] Therefore, a significant need exists for readily administrable medications of DMT to treat neurological diseases and conditions. Such medications, which maximize efficacy while enabling drug side effects to be effectively controlled, are of particular interest, especially if administrable via a convenient route, including self-administration.
[0009] Several attempts to develop psychedelic formulations using traditional polymeric formulations have been described. For example, U.S. Publication 2021/0015738. to La Rosa et al. entitled “Oral Dissolvable Film Containing Psychedelic Compound” discloses an oral dissolvable film with DMT to treat neurological conditions. The oral dissolvable film that includes: (a) plasticizer, (b) solvent, (c) sweetener, (d) flavoring agent, (e) binder, (f) coloring agent, (g) preservative, and (h) psychedelic compound selected from the group consisting of psilocybin, psilocin, baeocystin, mescaline. LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA. MDEA, MDA, and combinations thereof.
[0010] U.S. Publication No. 2021/0322306, to Espinoza, entitled “Oral Dissolvable Film With High Load of Polymeric Binder” discloses a composition comprising (a) a film matrix that includes one or more binders, wherein at least one binder is a polymeric binder having a glass transition temperature (Tg) of at least 45° C .; (b) solvent: (c) an active pharmaceutical ingredient (API); and (d) pharmaceutically acceptable excipient that includes at least one of a mucoadhesive polymer, plasticizer, filler, bulking agent, saliva stimulating agent, stabilizing and thickening agent, gelling agent, flavoring agent, taste masking agent, coloring agent, pigment, lubricant, release modifier, adjuvant, sweetening agent, solubilizer & emulsifier, fragrance, emulsifier, surfactant, pH adjusting agent, buffering agent, lipid, glidant, stabilizer, antioxidant, anti-tacking agent, humectant, and preservative.
[0011] The above publications did not study stability of the compositions disclosed therein. There remains a need for stable DMT compositions that are capable of providing controlled release of DMT, particularly for transmucosal delivery.
SUMMARY OF THE INVENTION
[0012] The present disclosure provides, in one respect, a pharmaceutical composition, comprising an amorphous DMT or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier. The amorphous DMT may be characterized by a powder x-ray diffractogram free of any discernable peaks and differential scanning calorimetry (DSC) spectra for absence of sharp melting endotherm of crystalline DMT and/or indication of phase change (e.g., glass transition temperature). Stability may be characterized by observing these features over time.
particularly after accelerated aging. The present inventors have unexpectedly found that DMT may be stabilized in an amorphous form within a polymeric carrier that is suitable for controlled transmucosal release of DMT. The stable amorphous DMT compositions may be provided in a form suitable for therapeutic transmucosal administration, e.g., buccal, or sublingual films.
[0013] The carrier may be a mucoadhesive polymer matrix. In some embodiments, the carrier matrix may comprise a cellulose derivative, a polyacrylic acid, a polyacrylate, a polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, poly(vinyl pyrrolidone-co-vinyl acetate), hydroxypropyl cellulose, hydroxypropyl methyl cellulose, propylene glycol alginate ester, tragacanth, alginate, a gum, a soluble starch, gelatin, lectin, pectin, or chitosan, or a mixture thereof.
[0014] In some embodiments, the composition may include a permeation enhancer, a buffering agent, and a saliva stimulating agent. The permeation enhancer may include a bile salt, cctvlpyridinium chloride (CPC), sodium laur l sulfate (SLS). Tween 80, L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, propylene glycol, dipropylene glycol, or ethanol, or a mixture thereof. The buffering agent may be citric acid, tartaric acid, fumaric acid, sodium citrate, sodium tartrate, or sodium fumarate, or a mixture thereof. The saliva stimulating agent may be citric acid, malic acid, lactic acid, ascorbic acid or tartaric acid, or a mixture thereof
[0015] In some embodiments, the pharmaceutical composition may also include a stability enhancer, wherein the stability enhancer is an antioxidant or chelator. The stability enhancer may be a-tocopherol, tocopherol acetate, L-Glutahione, L-cysteine, ascorbic acid, ascorbyl palmitate, propyl gallate, butylated liydroxvtoluene (BHT). butylated hydroxyanisole (BHA), Tocobiol or Ethylenediaminetetraacetic acid (EDTA), or a mixture thereof.
[0016] The composition may further comprise about 0% to about 10%, or about 0.1% to about 10% by weight of the buffering agent, about 2% to about 9% by weight of the buffering agent, or about 3% to about 8.5% by weight of the buffering agent.
[0017] The composition may further comprise about 0.1% to about 5% by weight of an antioxidant.
[0018] The composition may further comprise about 0% to about 8%, or about 0.1% to about 8% by weight of a saliva-stimulating agent.
[0019] In some embodiments, the pharmaceutical composition may further include hydrophilic adjuvants, 'additives or matrix solubilizing agent to promote water ingress and impacts film disintegration. It may include cellulose derivative, starch derivatives, cross linked povidone, cross
linked cellulose, cross linked starch or alginates, sucrose, maltose, maltodextrin, isomaltose, ascorbic acids, acids, acid salts, sugar alcohols or a mixture thereof.
[0020] The composition may further comprise about 0% to about 15% by weight of a hydrophilic adjuvants/additives or matrix solubilizing agent.
[0021] In some embodiments, the pharmaceutical composition may further include a plasticizer, wherein the plasticizer is a polyethylene glycol (PEG), propylene glycol, glycerol, triacetin, or castor oil, or a mixture thereof.
[0022] In some embodiments, the phannaceutical composition may further include a natural and/or artificial sweetener and/or flavoring agent. The sweetener may include sucrose, dextrose, fructose, glucose, maltose, maltitol. saccharin, sucralose, neotame, cyclamate, aspartame or acesulfame-K. or a mixture thereof. The flavoring agent comprises natural and / or synthetic flavor oils, oleoresins, and extract obtained from multiple parts of the plants such as leaves, fruits, flowers etc. The flavoring agent may include peppermint oil. cinnamon oil, vanilla extract, menthol, L-menthol or a mixture thereof.
[0023] The composition may further comprise about 0% to about 10% by weight of a sweetener.
[0024] The composition may further comprise about 0% to about 5% by weight of a flavoring agent.
[0025] In some embodiments, the pharmaceutical composition may further include natural colors such as cochineal dye, carotene, annatto dye. caramel dye etc. or synthetic coloring agents such as D&C and FD&C red. yellow, green, blue, inorganic/mineral colors (iron oxide red, iron oxide yellow, titanium dioxide etc.) The coloring agent is used alone or in combination.
[0026] The composition may further comprise about 0% to about 5% by weight of a coloring agent / color.
[0027] In certain embodiments, the carrier may include hydroxypropyl cellulose, a copolymer of N-vinyl-2-pyrrolidone and vinyl acetate, and hydroxypropylmethylcellulose. The carrier may further comprise polyethylene glycol, L-glutathione, citric acid, sucralose, maltitol, and L- menthol.
[0028] In some embodiments, the pharmaceutical composition may comprise (1) about 0.5 % to about 60 % by weight of an amorphous N-N-dimcthyltryptaminc or a pharmaceutically acceptable salt or prodrug thereof; (2) about 15% to about 80% by weight of a mucoadhesive polymer matrix; and (3) about 0.1% to about 30% by weight of a permeation enhancer. The composition may comprise about 20% to about 35% by weight of the N-N-dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof. The composition may comprise about 50% to about 60% by weight of the mucoadhesive polymer matrix. The composition may comprise about
0.5% to about 20% by weight of the plasticizer. The composition may comprise about 0.5% to about 5% by weight of the plasticizer. The composition may comprise, for example, a mucoadhesive polymer matrix that comprises hydroxypropyl cellulose, a copolymer of N-vinyl-2- pyrrolidone and vinyl acetate, and hydroxypropyl methylcellulose.
[0029] In some embodiments, the pharmaceutical composition may comprise N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof that is capable of being substantially fully solubilized and released in less than 1 minute following administration of the composition to a patient in need thereof.
[0030] In some embodiments, the pharmaceutical composition may comprise N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrag thereof that is capable of being substantially fully solubilized and released in greater than 1 minute and less than 20 minutes following administration of the composition to a patient in need thereof.
[0031] In some embodiments, the pharmaceutical composition may comprise N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrag thereof that is capable of being substantially fully solubilized and released in greater than 20 minutes and less than 3 hours following administration of the composition to a patient in need thereof.
[0032] In some embodiments, the composition is an oral fdm. The oral film may have a film thickness that is about 0.05 mm to about 0.4 mm.
[0033] In some embodiments, the invention relates to a method of treating a mental health condition or disorder, comprising administering a therapeutically effective amount of a composition above, wherein the mental health condition or disorder is major depressive disorder.
[0034] In some embodiments, the invention relates to a method of making a pharmaceutical composition, comprising the steps of: (1) combining N-N-dimetliyltn piamine or a pharmaceutically acceptable salt or prodrag thereof, and excipients in a solvent; (2) removing the solvent to provide a polymeric matrix comprising an amorphous N-N-dimethyltryptaniine or a pharmaceutically acceptable salt or prodrag thereof. The solvent may comprise methanol or an organic solvent in water, which may for example include a methanol-water in a 0:100 or 100:0 ratio. The method may comprise casting the polymeric matrix by removing the solvent. The solvent may include any organic solvent with a boiling point lower than water.
BRIEF DESCRIPTION OF THE FIGURES
[0035] FIG. 1 shows permeability of DMT formulations (1) citric acid / citrate and (2) methanol/water through prepared films of porcine buccal mucosa.
[0036] FIG. 2 shows a PXRD Spectra of DMT polymeric film Formulation 23 showing the presence of crystalline peaks indicative of DMT.
[0037] FIG. 3 A shows PXRD Spectra of DMT polymeric film Formulation 22 showing the absence of crystalline peaks, including any peaks indicative of DMT.
[0038] FIG. 3B shows PXRD Spectra of DMT polymeric film Formulation 24 showing the absence of crystalline peaks, including any peaks indicative of DMT.
[0039] FIG. 4A shows disintegration test for Formulations 22 and 23.
[0040] FIG. 4B shows disintegration test for Formulation 24.
[0041] FIG. 5 is a chart showing the dissolution profile for 40 mg DMT films in 500 mL buffer at pH 6 for formulations 22. 23. and 24.
[0042] FIG. 6 is a chart showing DMT permeation through porcine mucosa in phosphate buffered solution at pH=7 for formulations 22, 23. and 24, as well as for API (DMT in PBS).
[0043] FIG. 7A shows permeation of DMT films through porcine buccal mucosa in phosphate buffered solution 0.1M, pH=7.
[0044] FIG. 7B shows the effect of pH on DMT film permeation through artificial PermeaPad membrane in phosphate buffered solution 0.01M pH=7.
[0045] FIG. 8 shows DSC Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4)
[0046] FIG. 9 shows PXRD Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4)
[0047] FIG. 10A shows DSC Spectra of DMT polymeric film (Lot # RD-2021 Dec-01P4) 6 Month 25C/60% relative humidity.
[0048] FIG. 10B shows DSC Spectra of DMT polymeric film (Lot # RD-2021 Dec-01P4) 6 Month 40C/75% relative humidity.
[0049] FIG. 11A shows PXRD Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4) 6 Month 25C/60% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
[0050] FIG. 1 IB shows PXRD Spectra of DMT polymeric film (Lot # RD-2021Dec-01P4) 6 Month 40C/75% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
[0051] FIG. 12 shows dissolution profiles for 5 mg and 40 mg DMT films in 500 mL Buffer pH=6.8.
[0052] FIG. 13 A shows the study design for in-vitro tolerability of prepared buccal film evaluated using the EpiOral in vitro tissue model and evaluating cell viability using MTT assay.
[0053] FIG. 13B shows the results of cell viability testing after dosing according to the study design shown in FIG. 13 A.
DETAILED DESCRIPTION
[0054] The present invention relates to compositions of amorphous DMT which are capable of stabilizing DMT in amorphous form and providing controlled release of DMT in a suitable dosage form, for example, a transmucosal dosage form. The invention also relates to methods of making these amorphous DMT compositions, and methods of treatment of disease and disorders, e.g., neurological disorders, by administering these compositions to patients in need thereof.
[0055] Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties arc incorporated into this disclosure by reference for all purposes in order to describe the state of the art more fully as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications cited and this disclosure.
Definitions
[0056] For convenience, certain terms employed in the specification, examples and claims are collected here. Unless defined otherw ise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0057] The singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a pharmaceutically acceptable carrier” may include a plurality of pharmaceutically7 acceptable carriers, including mixtures thereof.
[0058] The term “and/or” is intended to mean either or both of two components of the invention.
[0059] The term “subject,” “individual” and “patient” are used interchangeably herein and refers to a human.
[0060] The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered and includes, but is not limited to, such liquids and powders that are hydrophilic substances, hydrophobic substances and substances that possess both hydrophilic and hydrophobic properties such as emulsifiers.
[0061] The term “device,” as used herein, refers to an apparatus or system capable of delivering a drug to a patient in need thereof.
[0062] The terms “administer.” “administering” or “administration” as used herein refer to administering a compound or pharmaceutically acceptable salt of the compound or a composition
or formulation comprising the compound or pharmaceutically acceptable salt of the compound to a patient.
[0063] The term “in need of treatment” and the term “in need thereof’ when referring to treatment are used interchangeably and refer to a judgment made by a caregiver (e.g., physician, muse, muse practitioner) that a patient will benefit from treatment.
[0064] The terms “treat” and “treatment” refer herein to therapeutic treatment, including prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change associated with a disease or condition. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of the extent of a disease or condition, stabilization of a disease or condition (i.e.. where the disease or condition does not worsen), delay or slowing of the progression of a disease or condition, amelioration or palliation of the disease or condition, and remission (whether partial or total) of the disease or condition. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the disease or condition as well as those prone to having the disease or condition or those in which the disease or condition is to be prevented. “Treatment” can, when concerning depression, also include reducing at least one sign or symptom of depression. Examples of a sign or symptom of depression include depressed mood, diminished interest in activities, weight loss or gain, decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to concentrate or indecisiveness, or suicidal ideation or behavior.
[0065] The term “pharmaceutically acceptable” as used herein, refers to a component of a pharmaceutical composition that is compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
[0066] The term “effective amount” or “therapeutically effective amount” as used herein, refers to the amount of active agent that elicits the biological or medicinal response in a tissue, system, or individual that is being sought by a researcher, healthcare provider or individual.
[0067] The term “neurological disease or condition” as used herein, means a disease or condition selected from: a neuropsychiatric disorder, such as depression (including severe depression such as treatment-resistant depression, major depressive disorder and persistent depressive disorder), catatonic depression, a depressive disorder due to a medical condition, postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder, anxiety, anxiety disorder, social anxiety disorder, general anxiety disorder (GAD), avolition disorder, bipolar disorder (including bipolar I disorder and bipolar II disorder), post-traumatic stress disorder, body dysmorphic disorder, abnormalities of mood or emotion, including the above conditions, dysthymia,
schizoaffective disorder, schizophrenia and other psychotic disorders, panic disorder, traumatic stress disorders, phobic disorders, and personality disorders with abnormal mood, such as borderline personality disorder, schizoid and schizotypal disorders and suicide ideation, or rumination/unproductive repetitive thoughts negatively impacting one’s behavior/mood/ability to focus, obsessive-compulsive disorder, addiction (including substance use disorder such as addiction to nicotine, alcohol, cocaine, opioids, amphetamine, methamphetamine, heroin, morphine, phencyclidine, 3, 4-methylenedioxy -methamphetamine, as well as other addictive substances), addictive behavior (including eating, gambling, sex, pornography, videogames, work, exercise, spiritual obsession, self-harm, travel and shopping addiction), eating disorder (including anorexia nervosa, bulimia nervosa and binge eating disorder), and pain (including pain associated with migraine or headache or chronic pain).
[0068] As used herein, the term “treatment-resistant depression’’ or “TRD’’ means a depressive disorder which does not respond satisfactorily to adequate treatment. TRD is a complex phenomenon influenced by variety in depressive subtypes, psychiatric comorbidity, and coexisting medical illnesses. Although TRD episodes are most commonly associated with major depressive disorder (MDD), they are also seen in the depressed phase of bipolar disorder.
[0069] As used herein, the term “onset” means the time to achieve maximum blood plasma concentration following administration (i.c., Tmax) and may also be described as “onset of action”. A “rapid onset” in the context of the present disclosure means that the drug achieves Cmax within about 20 minutes (e g., within about 2-10 minutes). However, onset following administration of a composition according to the present disclosure is less rapid, and consequently less “harsh” to the patient, than if DMT is administered by IV injection. In some cases, Tmax may be between 10 minutes and 90 minutes.
[0070] As used herein, the term “offset” means the time betw een the last time the concentration of DMT is at Cmax ± 10% and the first time the plasma concentration of DMT reduces to a threshold level below which the drug no longer has any meaningful therapeutic effect (c.g., about 250 nmol/L or 47.07 ng/mL). A “rapid offset” in the context of the present disclosure means less than about 10 minutes. However, although rapid, the offset is still sufficiently long for the drug to exert a reasonable duration of psychedelic effects.
[0071] The term “buccal delivery” or “buccal administration” refers to a route of administration in which the pharmaceutical dosage form is applied between the patient’s cheek and gum (i.e., the buccal cavity).
[0072] The term “sublingual deliver} ” refers to a route of administration in which the pharmaceutical dosage form is applied under the patient’s tongue.
[0073] The term “N, N-Dimethyltryptamine” or “DMT”, includes the compound of formula (I):
including pharmaceutically acceptable forms of DMT, including, but not limited to, salts, esters, polymorphs / solid state form, prodrugs. The term “DMT free form” or “DMT free base” refers to the compound of formula (I) without a pharmaceutically acceptable salt.
[0074] The term “pharmaceutically acceptable salt” as used herein with reference to “DMT or a pharmaceutically acceptable salt thereof’ means a pharmaceutically acceptable acid addition salt. Typically, acidic reagents may be used to prepare salts, in particular pharmaceutically acceptable salts, of DMT. Examples of suitable acidic reagents include fumaric acid, hydrochloric acid, tartaric acid, citric acid, hydrobromic acid, sulfuric acid, succinic acid, phosphoric acid, acetic acid, maleic acid, lactic acid, tartaric acid and gluconic acid. Often, the form of the DMT salt in a pharmaceutical composition of the present disclosure or otherw ise used according to the various aspects of the present disclosure, and embodiments thereof, is a pharmaceutically acceptable salt of a fumarate, hydrochloride, tartrate, succinate, or citrate salt, e.g., a fumarate salt.
[0075] The term “Amorphous”, as used herein refers to a solid that is lacking the three- dimensional long-range order of a crystalline material, possess a more random arrangement of molecules, and have physical properties such as its solubility etc., quite different from those of their corresponding crystalline states.
[0076] The term “microenviromental pH” also called “local pH” also called “surface pH” refers to the pH of the region of the carrier/polymeric matrix immediately surrounding the active agent as the matrix hydrates and/or dissolves, for example, in the mouth of the user. Buffering agent also influences the disintegration time of buccal film.
[0077] As used, herein, "transmucosal film” refers to polymeric film capable of embedding active ingredients which allows mucosal adhesion, complete solubilization or dissolution, diffusion and transmucosal delivery' of active for systemic absorption.
[0078] The term “Transmucosal”, as used herein, refer to any route of administration across the mucosal membrane. Examples include, but are not limited to, buccal, sublingual, gingival, on the tongue, nasal, vaginal, and rectal. In this embodiment, the administration route is buccal or sublingual.
[0079] The term “Mucoadhesion” refers to the phenomenon where polymers hydrates in presence of mucous fluid and adhere to the mucosal surface. Polymers that can readily form a gel in an aqueous environment can cause dehydration at the mucosal site of application. The water drawn into the film will help dissolving the active ingredient. Once the active ingredient is absorbed more water is absorbed by the remaining film due to a concentration gradient. This process leads to the mixture of formulation and mucus and can thus increase contact time with the mucous membrane. See, e.g., Mucoadhesive drug delivery systems, Flavia Chiva Carvalho, Marcos Luciano Bruschi , Raul Cesar Evangelista, Maria Palmira Daflon Gremiao, BJPS, vol. 46, n. 1, jan./mar., 2010.
[0080] The term “Polymeric carrier matrix or mucoadhesive polymeric matrix” refers to a carrier comprising combination of polymers with different functional properties such as but not limited to mucoadhesion, stabilizing (chemical and physical stabilizer), gelling, film forming, release controlling, swelling etc.
Pharmaceutical Compositions and Delivery
[0081] The present invention in one aspect involves oral transmucosal formulations in which an active ingredient comprising DMT is released in a therapeutically effective manner.
[0082] DMT is a natural occurring molecule and is a known psychedelic drug with rapid onset and relatively short duration effect. DMT is not active upon oral administration and converts to inactive metabolites in gastrointestinal tract (GI) and liver before sufficient penetration to the brain can occur which results in low oral bioavailability. Hence, in the present invention, alternate route of administration such as oral transmucosal (e.g., buccal /sublingual / gingival /mucosal (on the oral mucosa) or on the tongue is explored to improve DMT bioavailability by circumventing GI and hepatic first pass metabolism. See Metabolism GAP Analysis of DMT Literature. Gina Patel, Mpharm, PhD. President and CEO, Patel Kwan Consultancy, 25th August 2020.
[0083] DMT is believed to have good permeability across the biological membrane. However, DMT free form exhibited poor aqueous solubility and hence, from a buccal formulation permeability of DMT could be governed by the solubility of DMT at buccal mucosa. Hence, solubility enhancement of DMT at the site of absorption at buccal mucosa is required to achieve its bioavailability. Several approaches can be employed for solubility enhancement of DMT at buccal site such as employing, but not limited to. modifying physical form, salt, prodrug form of DMT, modification of microenvironmental pH, solubilizer, micronization. nanoparticles.
emulsions etc. In one aspect of the present invention, buccal formulations are design with an objective to modify polymorphic form / solid state form, preferably to amorphous form, to improve its solubility and thus the overall permeability across the buccal mucosa to achieve desired pharmacokinetics.
[0084] DMT free base is a lipophilic molecule (logP - 2.573) with a small backbone (Mol wt. 188.27 g/mol). The present inventors found that DMT may exist in several polymorph forms, including at least forms I-IV, with form IV of DMT being most stable among different forms studied. The present inventors also found that amorphous N,N-DMT exhibited a low glass transition temperature (-18 °C) and readily cry stallizes, particularly at temperatures above the Tg. For this reason, DMT is expected to have insufficient stability to be reliably delivered to the patient in amorphous form without a stabilizer.
[0085] The present inventors have discovered that by controlling the conditions upon which DMT is incorporated into a polymeric film, it is possible to obtain a film that includes DMT in a stable amorphous form suitable for transmucosal administration. For example, the conditions to achieve a stable DMT -containing film may include use of particular solvents in particular amounts alone or in combination with modifying the pH of the composition. These conditions may be provided to solubilized DMT within a casting solution whereby the casting solution is molded into a suitable form, and evaporation of solvent leads to the creation of the polymeric film. Alternatively, or in addition, the process may include spray drying tire polymer or stabilizer and DMT in a suitable solvent in order to incorporate DMT in a stable amorphous form. In some embodiments the resultant spray dried material may be directly incorporated into a polymeric film, or tablets or other suitable dosage forms.
[0086] As explained in further detail with respect to the examples of this application, appropriate control of pH and/or solvent conditions during formation of the DMT / polymer composition are important factors in achieving a stable amorphous DMT / polymer composition. The inventors have found that lowering pH of the DMT I polymer composition may result in ionization of the DMT molecule in a manner that could negatively impact transmucosal delivery. In this aspect, some combination of pH modulation and use of an appropriate solvent during DMT / polymer formation may be desirable in the preparation of a stable amorphous DMT I polymer composition.
[0087] The present invention, in one aspect, there contemplates incorporation of DMT into compositions and dosage forms, including but not limited to, fast dissolving tablets, microporous hollow fibers, chewing gum, tablets, fast or rapid disintegrating tablets, wafers, disks, powders, mucoadhesive gels, ointments, pastes, sponges, emulsions, single layer film, bilayer film, multilay ered film, mouthwashes, aerosols, spray s, drops, gummies, bi-layer or multi-layer tablets, mucoadhesive tablets etc. In one embodiment, preferred formulation is a buccal/subinguinal film.
These films may be divided in three main categories depending on the time for dissolution in the oral cavity. Quick Release (QR) film which solubilizes within seconds, generally less than a minute, other is moderate releasing film, which takes a few minutes to up to 20 minutes, and sustained release (SR) film, which solubilizes at a slower rate than moderate releasing film and takes more than 20min to up to few hours.
[0088] QR films release active in the oral cavity in seconds and offer less or no contact time with buccal or sublingual mucosa. However, moderate release or SR films offer longer contact time at the mucosal surface which increases the chance of the active ingredient to be directly absorbed through mucosa. Phannaccutical compositions comprising amorphous DMT or a pharmaceutically acceptable salt thereof suitable for buccal and sublingual administration include rapidly dissolving tablets, wafers, films, strips or patches, orodispersible tablets, oral gels, medicated lollipops, sprays, drops, gummies and other formulations that are retained on the buccal or sublingual mucosal surface.
[0089] In some embodiments, the examples of buccal / sublingual films include a rapid/quick release film (simply QR film) and moderate release composition comprising the drug present as a solid solution or a suspension form or a partially soluble form in a mucoadhesive polymeric carrier matrix, where upon administration of film in the oral cavity, the film disintegrates in a specified time to release drug and make it available for absorption through oral mucosa. QR films and moderate release fihns are designed to provide instantaneous release of the active ingredient after administration.
[0090] The present invention contemplates in one aspect, an amorphous DMT / polymer composition that includes one or more of matrix polymer or mucoadhesive polymer, permeation enhancer, plasticizer, antioxidant, buffering agent, and optionally sweetening agent, saliva stimulating agent, coloring agent, hydrophilic adjuvant / additive and/or flavoring agent.
[0091] Suitable mucoadhesive polymers include one or more polymers selected from cellulose derivatives, polyacrylic acids, polyacrylates, polyethylene oxides, polyvinyl pyrrolidones, poly(vinyl pyrrolidone-co-vinyl acetate), polyvinyl alcohols, propylene glycol alginate esters, tragacanth, alginates, gum (including karaya gum, guar gum, xanthan gum), soluble starch, gelatin, lectin, pectin, and chitosan. In some embodiments, the mucoadhesive polymer comprises one or more polymers selected from a hydrophilic polymer, a polysaccharide and its derivatives, and a hydrogel. In some embodiments, the mucoadhesive polymer comprises one or more polymers selected from polyacrylic acids, polyacrylates, celluloses, e.g., carboxycelluloses (e.g., sodium carboxymethyl cellulose), hydroxyalkyl cellulose (e.g., hydroxypropylcellulose, hydroxyethylcellulose and hydroxyethyl ethyl cellulose), polyvinylpyrrolidone, poly(vinyl pyrrolidonc-co-vinyl acetate) and polyvinyl alcohol. In some embodiments, the mucoadhesive
polymer comprises one or more polymers selected from Carbopol (poly acry lic acid), carboxymethyl cellulose, carboxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and gum. In some embodiment, the mucoadliesion is attributed to material containing thiol group such as but not limited to, N-acetyl cysteine, glutathione, thiolated polycarbophil (a copolymer of acrylic acid and divinyl glycol), thiolated chitosan, thiolated sodium carboxymethylcellulose, thiolated sodium alginate, thiolated sodium hydroxypropyl cellulose, thiolated hyaluronic acid and thiolated pectin. See. e.g., Thiolation of Biopolymers for Developing Drug Delivery Systems with Enhanced Mechanical and Mucoadhesive Properties: A Review. Vivek Puri, Ameya Sharma, Pradeep Kumar, Inderbir Singh. Polymers 2020. 12, 1803; doi:10.3390/polyml2081803. In some embodiments, the mucoadhesive polymer is water- swellable. Typically, the mucoadhesive polymer is present alone or in combination in a total amount of about 15% to about 80% by weight of the film composition.
[0092] The film compositions can further include a permeation enhancer. For example, in some embodiments, the film composition comprises a permeation enhancer, e.g., comprising one or more permeation enhancers selected from bile salts such as sodium deoxycholate (SDC), including sodium glycodeoxycholate (SGDC), sodium taurodeoxycholate (STDC) and others; synthetic surfactants such as Cetylpyridinium chloride (CPC), Sodium lauryl sulfate (SLS) Tween 80 and others but not limited to L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, propylene glycol, dipropylene glycol, ethanol, and surfactants. In some embodiments, the permeation enhancer is present in an amount of about 0.1% to about 30% by weight of the film composition.
[0093] In some embodiments, the film composition can further include an antioxidant, e.g., comprising one or more antioxidants such as a-tocopherol, tocopherol acetate, L-Glutahione, L cysteine, ascorbic acid, ascorbyl palmitate, propyl gallate, butylated hydroxy toluene (BHT), butylatcd hydroxy anisole (BHA). Tocobiol and Ethylenediaminetetraacetic acid (EDTA). In some embodiments, the antioxidant is present in an amount of about 0.1% to about 5% by weight of the film composition.
[0094] The film compositions can further include plasticizer. A plasticizer improves the flexibility of the film and reduces the brittleness of the film by reducing the glass transition temperature of the film. For example, in some embodiments, the film composition comprises plasticizer e.g., comprising one or more plasticizers selected from but not limited to polyethylene glycols (PEGs) such as PEG 300. PEG 400 etc.; propylene glycol, glycerol, triacetin, castor oil. In some embodiments, the plasticizer is present in an amount of about 0.5% to about 20% by weight of the film composition.
[0095] The film compositions can further include sweetening agent to improve the taste. The stimulation of saliva production increases the saliva production that would aid in faster solubilization of film and active for faster absorption. In some of the examples natural or artificial sweeteners, are used to improve the palatability of the formulation. For example, in some embodiments, the film composition comprises sweetener e.g., comprising one or more selected from but not limited to sucrose, dextrose, fructose, glucose, liquid glucose, maltose, maltitol. saccharin, sucralose, neotame, cyclamate, aspartame and acesulfame-K etc. In some embodiments, the sweetner is present in an amount of about 0% to about 10% by weight of the film composition.
[0096] The film compositions can further include a saliva stimulating agent. In some of the examples, citric acid, malic acid, lactic acid, ascorbic acid, succinic acid, fumaric acid and tartaric acid are used as salivary stimulants. Stimulating agents are used alone or in combination between about 0% to about 8% or about 0.1 to about 8% w/w of weight of the dry film composition.
[0097] The film composition can further include a flavoring agent. In some examples natural and / or synthetic flavor oils, oleoresins, and extract obtained from multiple parts of the plants such as leaves, fruits, flowers etc. such as peppermint oil, cinnamon oil, vanilla extract, menthol. L- menthol or a mixture thereof are used as flavoring agent. In some embodiments, the flavoring agent is present in an amount of about 0% to about 5% by weight of the film composition.
[0098] The film composition can further include hydrophilic adjuvants/additives or matrix solubilizing agent to promote water ingress and impacts film disintegration. In some of the examples cellulose derivative, starch derivatives, cross linked povidone, cross linked cellulose, cross linked starch or alginates, sucrose, maltose, maltodextrin, isomaltose, ascorbic acids, acids, acid salts, sugar alcohols or a mixture thereof are used as hydrophilic adjuvants/additives or matrix solubilizing agent. In some embodiments, the hydrophilic adjuvants/additives or matrix solubilizing agent is present in an amount of about 0% to about 15% by weight of the film composition.
[0099] The film composition can further include include natural colors such as cochineal dye, carotene, annatto dye, caramel dye etc. or synthetic coloring agents such as D&C and FD&C red. yellow, green, blue, inorganic/mineral colors (iron oxide red, iron oxide yellow, titanium dioxide etc.) The coloring agent is used alone or in combination. In some embodiments, the coloring agent is present in an amount of about 0% to about 5% by weight of the film composition.
[0100] DMT is weak base with pKa of 8.86. The pH of the film plays a very important role in balancing its ionized vs unionized form at the site. In the present invention microenvironmental pH is maintained to achieve balance between ionized and unionized form and thus the permeation across the mucosa.
[0101] In one aspect, the polymeric film surface pH / diffusion environment, also called microenvironmental pH, may be maintained to desired pH close to physiological pH of saliva. The microenvironmental pH can be adjusted and /or maintained by adjusting polymeric film pH utilizing methods including, but not limited to, the use of acid, base, buffering agent in die formulation.
[0102] The film composition can include acid, base or buffering agent which could influence the pH and help maintain desired microenviromental pH at the site of application in the oral cavity. In some embodiments, the film composition comprises of acid, base or buffering agent, not limited to, citric acid, tartaric acid, fumaric acid, sodiimi citrate, sodium, tartrate, sodium fumarate etc. Buffering agent are used alone or in combination bet een about 0% to about 10% or about 0.1 to about 10 % w/w of the film composition.
[0103] Addionally, a inactive backing layer may be added on top of the active film to make it bilayer film in order to reduce or prevent erosion from the back side of the film when applied to the mucosal surface. Backing layer may furher help to improve taste of the film.
[0104] The amount of active e.g., DMT or its suitable form, to be incorporated into the polymeric fdm depends on the desired dosage to be administered. For example, DMT or its suitable form can be present in about 0.5 % to about 60 % by weight of film.
[0105] One additional benefit of buccal or sublingual film is that less dose is required to achieve desired bioavailability in contrast to an oral dose which needs co-administration of monoamine oxidase inhibitors to achieve DMT oral bioavailability. See, e.g.. N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past. Present, and Future Research to Determine Its Role and Function. Steven A. Barker, Front. Neurosci.. 06 August 2018 https://doi.org/10.3389/fnins.2018.00536.
[0106] In some embodiments, buccal or sublingual films were prepared with a thickness range from about 0.01 mm to about 1.5 mm, and more specifically from about 0.05 to about 0.4 mm. Further, the thickness of the film could be varied from 10 % to 90 % to these ranges based on the drug-polymeric mixture.
[0107] The prepared films were evaluated for physicochemical properties such as appearance, disintegration time, dissolution, assay, water content, degradation products, polymorphic form evaluation, mechanical properties such as folding endurance, elongation, tensile strength etc. and ex-vivo permeability through porcine buccal mucosa or permeapad membrane.
DMT Solubility Evaluation
[0108] Solubility studies of DMT have been carried out in various solvents by preparing super saturated mixture and analyzed using HPLC. The results shown below.
[0109] Results of DMT solubilization with different solvents is shown in Table 1.
[0110] The solubility study was performed on DMT API as is, the crystalline form, and the results showed poor water/aqueous solubility. This warrants a strong need for improvement solubility of DMT API in the film fonnulation for better bioavailability.
[01U] The present work also aims to convert API to its amorphous form to improve solubility and maintaining same form in the fonnulation throughout the shelf life. Suitable methods of manufacturing has been chosen to convert DMT into amorphous form and various combinations of polymers have been incorporated in the formulation to stabilize the amorphous fonn in the film during the shelf life. The choice of polymers includes one or more polymers selected from cellulose derivatives, polyacrylic acids, polyacrylates, polyethylene oxides, poly vinyl pyrrolidones, poly(vinyl pyrrolidone-co-vinyl acetate), polyvinyl alcohols, propylene glycol alginate esters, tragacanth, alginates, gum (including karaya gum, guar gum, xanthan gum), soluble starch, gelatin, lectin, pectin, and chitosan. In some embodiments, the polymer comprises one or more polymers selected from a hydrophilic polymer, a polysaccharide and its derivatives, and a hydrogel. In some embodiments, the polymer comprises one or more polymers selected from polyacrylic acids, polyacrylates, celluloses, e.g., carboxycelluloses (e.g.. sodium carboxymethyl cellulose), hydroxyalkyl cellulose (e.g., hydroxypropylcellulose, hydroxyethylcellulose and hydroxyethyl ethyl cellulose), polyvinylpyrrolidone, and polyvinyl
alcohol. In some embodiments, the polymer comprises one or more polymers selected from Carbopol (polyacrylic acid), carboxymethyl cellulose, carboxyethyl cellulose, hydroxy propyl cellulose, hydroxypropylmethyl cellulose, and gum.
[0112] Further, several excipients for formulating transmucosal films with desired properties have been analyzed for compatibility7 with DMT at 50°C/75%RH utilizing HPLC method to detect impurity' levels. The results arc shown in Tabic 2 below.
[0113] A forced degradation study of DMT was performed under different stress conditions and samples are analyzed using HPLC. The results are shown in Table 3 below.
[0114] DMT has been shown to be highly prone to oxidation upon force degradation study as suggested by the data in the above table. It is important to incorporate antioxidant(s) in the formulation to prevent oxidation of DMT during the shelf life and to form stable films.
[0115] From solubility, forced degradation and compatibilities studies various functional and non-functional excipients have been selected along with several others for further studies. Methods of DMT film manufacturing
[0116] Different manufacturing techniques such as solvent casting method, hot-melt extrusion, semisolid casting, solid dispersion extrusion, rolling method etc. can be used for DMT polymer formation, for example in the preparation of transmucosal (e.g., buccal, sublingual etc.) film manufacturing. The solvent casting method is the most preferred method for the manufacturing of buccal film and has been well studied in the past. The buccal film of DMT is manufactured using the solvent casting method. DMT as Form I (Investigations into the polymorphic properties of N.N-dimethyltryptamine by X-ray diffraction and differential scanning calorimetry, Gaujac et al (2013)) or Form IV and excipients are mixed with suitable solvent system to form a uniform mixture with DMT in solution form. The resulting mixture is subjected to deaeration, used to cast
a film, allowed to dry to obtain films containing DMT as amorphous form. The films are then cut into strips of desired sizes to produce desired film strengths of DMT.
[0117] In present work the solvents have been selected to solubilize DMT completely in the mixture and upon casting and dry ing to evaporate solvent/s to form amorphous DMT in the polymer matrix. The well-known techniques like PXRD and DSC have been utilized to confirm the conversion to the amorphous form.
[0118] In some examples of present invention DMT alone and films containing DMT as amorphous and/or crystalline form have been prepared in combination with other excipients to achieve solubility and permeability. Example 1
[0119] In an exemplary embodiment, DMT polymeric films were prepared according to the formula given in table 4 below.
[0120] The film using the above composition was prepared as follows: DMT and excipients were mixed with either water-based citrate buffer or methanol - water (70:30) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a deaerated mixture, dried and cut into strips.
[0121] Further, permeability of DMT through prepared films were evaluated using ex-vivo permeation study i.e., using porcine buccal mucosa as presented below. Ex-vivo permeation is well studied using Franz diffusion cell or Using chambers utilizing animal mucosa (e.g., Pig or sheep buccal mucosa) or by using commercially available synthetic membranes (e.g., Permeapad®). The Franz diffusion cell consists of two compartments; one is the donor compartment, the other is the receptor compartment of 18 mL capacity and having 0.785 cm2 effective diffusion area. The temperature is maintained at 37°C by water jacket. This technique can also establish good discrimination tool to optimize formulation composition to achieve desired permeability and determine time required for film to be retained at the buccal surface to offer desired rate and extent of DMT absorption. Films prepared using aqueous as well as hydroalcoholic mixture demonstrated permeability of DMT across the porcine buccal mucosa as shown in FIG. 1
Example 2
[0122] In an exemplary embodiment, DMT polymeric film formation were evaluated using different matrix forming polymers or combination thereof, according to the formula given in
[0123] The film using the above composition was prepared as follows: DMT and excipients are mixed with methanol - water (70:30) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a de-aerated ix lure, dried and cut into strips.
5 DMT films were successfully prepared using all the composition as presented in the above table.
Example 3
[0124] In various embodiments, DMT observed to be extensively degrade under oxidative stress. Thus, antioxidant(s) I Chelating agent were incorporated in the buccal / sublingual film to stabilize DMT. Films were prepared using different antioxidant using solvent casting method as0 described in example 2 having the compositions shown in Table 6 below.
[0125] Stability of prepared films were evaluated at 40°C /75 % RH for 8 weeks utilizing HPLC method to detect impurity levels as shown in Table 7 below. 5
[0126] From the above stability results, antioxidants were found to improve stability of DMT in polymeric films.
Example 4 [0127] Further, stability of DMT was studied at various levels of L-glutathione. Thus, DMT films were prepared using solvent casting method and evaluated for stability utilizing HPLC method as described in Table 8 below.
[0128] Stability of prepared films were evaluated at a higher temperature of 50oC for Iweek utilizing HPLC method as shown in Table 9 below.
[0129] L -Glutathione at levels of both 0.83% and 1.3% showed good stability up to Iweek at 50 °C temperature.
Example 5
[0130] To evaluate the impact of physical form of DMT on disintegration, dissolution, and permeability' across pig buccal mucosa, DMT polymer films were prepared using different solvent composition with and without citric acid according to the formula given in the table 10 below.
[0131] The DMT films using the above composition were prepared as follows: DMT and excipients are mixed with either water (100 %) or methanol - water (50:50) solvent mix to form a homogenous mixture also called blend. The resulted mixture was de-aerated. The film was casted using a de-aerated mixture, dried and cut into strips. The films were characterized for DMT form using PXRD as presented shown in FIGs. 2 and 3A-3B. FIG. 2 shows the PXRD Spectra of DMT polymer film Formulation 23 (Crystalline Peaks of DMT-Present). FIG. 3 A shows the PXRD Spectra of polymer film Formulation 22 (Crystalline Peaks of DMT-Absent). FIG. 3B shows the PXRD Spectra of polymer film Formulation 24 (Crystalline Peaks of DMT-Absent).
[0132] Based on the PXRD results it was confirmed that DMT is present in amorphous form in formulation 22 and 24. In formulation 22 and 24 DMT was present completely in a solution form in the blend resulting in a film with amorphous DMT. In formulation 24, DMT was completely solubilized in the blend despite excluding of methanol, principally due to the presence of citric acid which helps DMT to completely solubilize in 100 % water phase by lowering the blend pH and finally yielded a film with amorphous DMT.
[0133] Whereas in formulation 23, DMT was present in crystalline form due to exclusion of methanol and citric acid w hich are necessary to help DMT completely dissolve in the blend.
[0134] Based on the above results it is inferred that, DMT should be completely dissolved in the blend to achieve a film formulation w ith amorphous DMT.
[0135] Further, prepared films were evaluated for film disintegration and dissolution to understand the impact of DMT physical form in film formulation as shown in Figs. 4A-4B.
[0136] Disintegration Time of Formulation 24
[0137] Based on the above presented disintegration results it was confirmed that films with amorphous API (Formulation 22 and 24) rapidly disintegrated within 5 minutes and formed clear solutions in PBS pH 7.0 whereas the film with crystalline API (Formulation 23) showed delayed disintegration at about 15 minutes and film residues were not completely solubilized even after 35 minutes in PBS pH 7.0. Longer disintegration time is not desired for DMT film formulation as it increases chances to sw allow undissolvcd residue which ultimately gets deactivated in GI tract and liver. The disintegration results for Formulations 22-24 are shown in FIG. 5.
[0138] Dissolution profile of 40 mg DMT films (Formulation 22, 23 & 24) in 500 mL Buffer pH 6.8
[0139] Based on the above presented dissolution results it was confirmed that film with amorphous API (Formulation 22 & 24) showed rapid drug release and more than 80 % drug is dissolved within 5 minutes. On the other hand, film with crystalline API (Formulation 23) showed slower dissolution during 5 min. and 10 min. timepoint as compared to amorphous API film. At 15 minutes all three formulations showed complete drug release which is attributed to the complete sink condition in 500 mL of dissolution media volume for film.
[0140] Further, all prepared films are evaluated for the permeability through pig buccal mucosa and compared against the permeability of API dispersion in PBS pH 7.0 as presented in FIG. 6. In one aspect, the present invention involves a DMT polymeric film that releases about 5% or less DMT in 60 minutes, about 15% DMT or less in 180 minutes when measured through pig mucosa in phosphate buffered solution 0.01M pH=7, as shown in FIG. 6. These conditions are seen to be satisfied by formulations 22 and 24 and are not satisfied by formulation 23 or DMT active
pharmaceutical ingredient (API) not present in a polymer matrix. The formulation 23 exhibited permeation comparable to the DMT API. For example, at around 180 minutes formulation 23 exhibited approximately 29% while the DMT API exhibited about 33% release as shown in FIG. 6.
[0141] Based on the above presented results, DMT exhibited permeability through pig buccal mucosa for films with amorphous DMT (Formulation 22 & 24), crystalline DMT (Formulation 23) and DMT dispersion in PBS pH 7.0.
[0142] Further, permeability of DMT fdm (Formulation 23) and DMT dispersion in PBS pH 7.0 was found to be higher as compared to the Formulation 22 and 24 fdm which could be attributed to pH of the donor chamber media. Formulation 23 and DMT dispersion in PBS exhibited pH of 8.9 and 9.5 respectively which is close to the pKa of DMT 8.68 and thus it is believed that for formulation 23 and DMT dispersion more unionized DMT could be present in the donor chamber resulting in higher permeability' than formulation 22 and 24 fdms which exhibited pH of 7.6 and 7.8 respectively where more ionized DMT could be present.
[0143] Further, to understand the impact of film pH on in-vitro permeability, films with different surface pH were prepared as presented in example 6.
Example 6
[0144] In an exemplary embodiment, DMT polymer films were prepared according to the formula given in the table below. The films were prepared with different levels of citric acid to produce pH in the range of pH 5 to 10 and the effect of pH was evaluated for permeability as shown m Table 11.
[0145] The DMT films using the above composition were prepared as follows: DMT and excipients are mixed with methanol - water (70:30) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a de-aerated mixture, dried and cut into strips. The films were measured for surface pH and data presented in above composition table.
101461 Further, permeability of DMT through prepared films were evaluated using ex-vivo permeation study i.e., porcine buccal mucosa or Permeapad® as presented below.
[0147] The Permeapad® (Certificate No. 014557268) is the barrier consist of support layer and lipid layer. The barrier is made up of soy phosphatidylcholine S-100 as the lipid layer. In brief, a thin layer of lipid is applied to a hydrophilic support sheet (Piltz GmbH, Taunusstein, Germany) in organic solution. The solvent is allowed to evaporate to form the barrier. Permeability of the model drug metoprolol was detennined across Penneapad® and compared to literature data for permeation across TR146 cell layers, porcine buccal mucosa ex vivo and in Gottingen minipigs. The results showed a good correlation between Permeapad® and the respective in vitro studies, which indicated that Permeapad® appears useful as a predictive assay for pH dependent permeability for this basic drug substance. Permeapad® is suggested as a preliminary permeability tool for buccal absorption of metoprolol. An excellent 2 IVIVC (R = 0.98) was obtained when comparing Papp to the absolute bioavailability of metoprolol administered buccally in the form of a gel to mini-pigs, indicating that in the case of metoprolol Permeapad® can be used to mimic buccal mucosa as a faster and less laborious meth- od as compared to any of the other mentioned methods. See Use of Permeapad® for prediction of buccal absorption: A
comparison to in vitro, ex vivo and in vivo method, Hanady Ajine Bibi a, Rene Holm b,l, Annette Bauer-Brandl a,
[0148] FIG. 7A shows permeation of DMT films through porcine buccal mucosa in phosphate buffered solution 0.01M, pH = 7. FIG. 7B shows the effect of pH on DMT film permeation through artificial PermeaPad membrane in phosphate buffer solution 0.0 IM, pH=7.
[0149] Stability of prepared films were evaluated at 50oC RH weeks utilizing HPLC method to detect impurity levels as shown in Table 12 below.
[0150] The surface pH has showed impact on permeation rate. Films with tw o extreme levels of citric acid 0%w/w and 9.3% w/w produced surface pH of 9.2 showed better permeation compared to pH 5.7 films respectively. Formulations with citric acid level of 5.0% and 8.2% w/w citric acid produces pH close to saliva pH in oral cavity, as pH 8.2 and 7.5 respectively and both fonnulations showed satisfactory' permeability with artificial membrane as presented in graph. Iwk stability at 50C temperature for all fonnulations showed promising data. Based on the penneability and stability studies, formulation containing citric acid level 4.0-9.0 % w/w, more preferably with level 5.0-8.5 % w/w is preferred.
Example 7
[0151] In an exemplary embodiment. DMT polymer film were prepared according to the formula given in table 13 below.
The buccal/sublingual film using above composition were prepared as follows: DMT and excipients arc mixed with methanol - water (50:50) solvent mix to form a homogenous mixture. The resulted mixture was de-aerated. The film was casted using a de-aerated mixture and dried until loss on drying (LOD) of the dried film is achieved, preferably within 5 to 11 % w/w to form flexible film sheets. The thickness of the flexible film sheets is preferably within 0.05 - 0.40 mm. The prepared film sheets comprise amorphous DMT preferably within 3-7 mg/cm2. The individual prepared films were cut into strips of varied sizes and/or weight to achieve any strength, including from 2.5mg to 80mg. Preferably from 5mg to 40mg. From above batch sheet was cut to form four strengths of 5mg. lOmg, 20mg and 40mg. Prepared films are characterized for mechanical properties as presented in Table 14 below.
[0152] Stability of prepared films were evaluated at 2-8C, 25°C/60%RH. 40°C/75%RH for 5mg and 40mg strengths utilizing bracketing approach as presented in Tables 15-20 below.
[0153] Further during the manufacturing of buccal film, cr stalline form of DMT (Form I or IV) was used to manufacture a polymeric film and die manufacturing process produced amorphous form of DMT in the film formulation. Conversion of the amorphous form was confirmed using PXRD and DSC spectra as presented below. Specifically, it is noted that die PXRD diffractogram is free of crystalline peaks. Whereas the DSC spectrum lacks sharp melting endotherm of crystalline DMT and / or indication of phase change (e.g., glass transition temperature).
Conversion of DMT to amorphous form is critical for the buccal film formulation to achieve high aqueous solubility to ensure drug solubilization at the mucosal surface in buccal cavity' to facilitate transmucosal permeation of DMT and systemic absorption as shown in FIG. 8. The PXRD Spectra of DMT Polymer Film (Lot # RD-2021 DEC-01P4) is shown in FIG. 9. confirming the absence of crystalline peaks, including any peaks associated with DMT.
[0154] In the present invention amorphous form of DMT has been generated successfully using combination of various polymers. Further, addition of these polymers helps keep stable amorphous form in the film even under accelerated storage condition i.e., room temperature (25°C/60%RH) and even at worst conditions of 40°C/75% RH up to 6M as shown in Figs. 10A- 10B. FIG. 10A shows DSC Spectra of Polymer Film (Lot # RD-2021Dec-01P4) 6 Month 40°C/75% relative humidity. FIG. 10B shows DSC Spectra of DMT Polymer Film (Lot # RD- 2021Dec-01P4) 6 Month 40°C/75% relative humidity.
[0155] FIG. HA shows the shows PXRD Spectra of DMT Polymer Film (Lot # RD-202 IDec- 01P4) 6 Month 25°C/60% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT. FIG. 1 IB shows PXRD Spectra of DMT Polymer Film (Lot # RD- 2021Dec-01P4) 6 Month 40°C/75% relative humidity showing the absence of crystalline peaks, including any peaks indicative of DMT.
[0156] The buccal film was tested for disintegration with 20mL Phosphate Buffer Saline pH 7.0 in Petri dish. The film disintegration time was found to be between 3-10 minutes.
[0157] Also, the solubility of buccal film and neat API (crystalline DMT) was measured in Phosphate buffer saline pH 6.8 and found to be 24.6mg/mL and 2.3mg/mL respectively. This improved solubility also suggests there was a several fold increase in solubility of DMT in polymeric films compared to its crystalline form.
[0158] Further, dissolution of 5mg and 40mg Polymer Film was carried out in 500 mL phosphate buffer pH 6.8 using USP type 2 dissolution apparatus at 50 rpm. Dissolution data are presented in the below graph. Film showed rapid dissolution with complete drug release within 15 minutes. Stability of these films are evaluated at 2-8°C. 25°C/60 % RH and 40 °C/75 % RH for 6 months and all films showed rapid dissolution with more than 85 % drug release in 15 minutes further
confirming amorphous form retention in film formulation. FIG. 12 shows dissolution profiles for 5 mg and 40 mg DMT films in 500 mL Buffer pH=6.8.
[0159] Further, in-vitro tolerability of prepared buccal film was evaluated using the EpiOral in vitro tissue model and evaluating cell viability using MTT assay. The study design and cell viability results are shown in FIGs. 13A and 13B, respectively.
[0160] The study was performed using positive control with 1.0% Triton X100 and a negative control without dosing the formulation. The samples included neat API in acidic and basic solutions along with placebo and formulated DMT films at different time points as shown in above study design.
[0161] The results based on cell viability were presented as bar graph in above figure showed promising values at 10, 20 and up to 60 minutes when comparing with negative control and positive control. The film showed faster disintegration time less than lOminutes and about 90% dissolution in 5minutes. DMT polymer film was found to demonstrate more than 80 % cell viability at 20 minutes time point and based on disintegration and dissolution data, it is expected that film will dissolve in buccal mucosa within 20 minutes. Hence, DMT polymer film is unlikely to cause buccal mucosal irritation during the clinical studies.
[0162] Based on the physicochemical characterization, in-vitro tolerability and ex-vivo permeability data it is expected that the amorphous fonn of DMT from the film formulation will be sufficiently solubilized I rapidly dissolved at the buccal site. Further, based on the favorable surface pH, solubilized fonn of DMT should exhibit rapid transmucosal permeability (rapid onset) and in-vivo bioavailability.
Example 8
[0163] Alternatively, or in addition, amorphous DMT can also be manufactured using spray drying process. Breifly, polymer and/or stabilizer and DMT are mixed in a suitable solvent /s mixture to form a solution followed by spray drying at controlled conditions to form stable amorphous DMT powder. The composition of this polymer is shown in Table 21 below.
[0164] Further, amorphous DMT can be formulated as tablets using direct compression process.
Brefily, spray dried N,N Dimethyltryptamine powder is blended with filler/diluent, binder, disitegrant, glidant and lubricant to produce a powder blend which is subssequantly compressed to form a tablet. The composition of such tablet is shown in Table 21 below.
[0165] Furthermore, amprophous DMT can also be formulated as polymeric film, tablets such as fast or rapid disintegrating tablets, rapidly dissolving tablets, orodispersible tabelts, bi-layer or multi-layer tablets, mucoadhesive tablets, etc. or any other suitable dosage form. [0166] Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. All references cited herein, including all U.S. and foreign patents and patent applications, are specifically and entirely hereby incorporated herein by reference. It is intended that the
specification and examples be considered exemplary only, with the true scope and spirit of the invention indicated by die following claims.
Claims
1. A composition comprising a pharmaceutically effective amount of an amorphous N.N- dimethyltryptamine (DMT) incorporated within a polymeric carrier matrix.
2. The composition of claim 1, wherein the DMT is characterized by a powder x-ray diffractogram free of any discernable peaks.
3. The composition of claim 1, wherein the DMT is characterized by a differential scanning calorimetry (DSC) spectrum lacking a sharp melting endotherm of cry stalline DMT and/or lacking an indication of phase change.
4. The composition of claim 1, wherein the polymeric carrier matrix is a mucoadhesive polymer.
5. The composition of claim 1, wherein the DMT is a DMT free base.
6. The composition of claim 1, wherein the pharmaceutical composition is capable of producting a TIIOX between lOmin to 90min upon administration.
7. The composition of claim 1, wherein the polymeric carrier matrix is suitable for transmucosal application.
8. The composition of claim 7, wherein the transmucosal application is buccal, sublingual, gingival, on the tongue, nasal, vaginal, or a rectal application.
9. The composition of claim 7, wherein the transmucosal application is a buccal application.
10. The composition of claim 1, wherein the polymeric carrier matrix comprises a cellulose derivative, a polyacrylic acid, a polyacrylate, a polyethylene oxide, polyvinyl pyrrolidone. poly(vinyl pyrrolidone-co-vinyl acetate), hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, propylene glycol alginate ester, tragacanth, alginate, a gum, a soluble starch, gelatin, lectin, pectin, or chitosan, or a mixture thereof.
11. The composition of claim 1. further comprising a permeation enhancer, a buffering agent, and a saliva stimulating agent.
12. The composition of claim 11, wherein the permeation enhancer is a bile salt, cetylpyridinium chloride (CPC), sodium lauryl sulfate (SLS), Tween 80, L-menthol, dimethyl sulfoxide (DMSO), oleic alcohol, oleic acid, oleyl oleate, levulinic acid, propylene glycol, dipropylene glycol, ethanol, or mixtures thereof.
13. The composition of claim 11. wherein the buffering agent is citric acid, tartaric acid, fumaric acid, succinic acid, malic acid, sodium citrate, sodium tartrate, sodium succinate, sodium fumarate, or mixtures thereof.
14. The composition of claim 11. wherein the saliva stimulating agent is citric acid, malic acid, lactic acid, ascorbic acid, tartaric acid, or mixtures thereof.
15. The composition of claim 11, further comprising a stability enhancer including an antioxidant or a chelator.
16. The composition of claim 15, wherein the stability enhancer is a-tocopherol. tocopherol acetate, L-Glutahione, L-cysteine. ascorbic acid, ascorbyl palmitate, propyl gallate, butylated hydroxytoluene (BHT). butylated hydroxyanisole (BHA), Tocobiol, Ethylenediaminetetraacetic acid (EDTA), or mixtures thereof.
17. The composition of claim 11, further comprising a plasticizer.
18. The composition of claim 17, wherein tire plasticizer is a polyethylene glycol (PEG), propylene glycol, glycerol, triacctin, castor oil, or mixtures thereof.
19. The composition of claim 11, further comprising a sweetener and/or flavoring agent.
20. The composition of claim 11, further comprising a sweetening agent including sucrose, dextrose, fructose, glucose, maltose, maltitol, saccharin, sucralose, neotame, cyclamate, aspartame, acesulfame-K, or mixtures thereof.
21. The composition of claim 11, further comprising a flavoring agent including peppermint oil, cinnamon oil, vanilla extract, menthol, L-menthol, or mixtures thereof.
22. The composition of claim 11, further comprising a coloring agent including D&C or FD&C red, yellow, green, blue, iron oxide red, iron oxide yellow, titanium dioxide or mixtures thereof.
23. The composition of claim 11, further comprising a hydrophilic adjuvant/additive or matrix solubilizing agent wherein hydrophilic adjuvant and/or additive is cellulose derivative, starch derivative, cross linked povidone, cross linked cellulose, cross linked starch or alginate, sucrose, maltose, sugar alcohol or mixtures thereof.
24. The composition of claim 1, wherein the polymeric carrier matrix comprises hydroxypropyl cellulose, a copolymer of 1 -vinyl-2 -pyrrolidone and vinyl acetate, and hydroxypropyl methylcellulose.
25. The composition of claim 24, further comprising polyethylene glycol. L-glutathione. citric acid, sucralose, maltitol, and L-menthol.
26. A composition, comprising: about 0.5 % to about 60 % by weight of an amorphous N-N-dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof; about 15% to about 80% by weight of a mucoadhesive polymer matrix; and about 0.1% to about 30% by weight of a permeation enhancer.
27. The composition of claim 26, comprising about 20% to about 35% by weight of the N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof.
28. The composition of claim 26, comprising about 50% to about 60% by weight of the mucoadhesive polymer matrix.
29. The composition of claim 26, further comprising about 0.5% to about 20% by weight of a plasticizer.
30. The composition of claim 26, comprising about 0.5% to about 5% by weight of the plasticizer.
31. The composition of claim 26, further comprising about 0.1% to about 10% by weight of a buffering agent.
32. The composition of claim 26, comprising about 2% to about 9% by weight of the buffering agent.
33. The composition of claim 26, comprising about 3% to about 8.5% by weight of the buffering agent.
34. The composition of claim 26. further comprising about 0.1% to about 5% by weight of an antioxidant.
35. The composition of claim 26. further comprising about 0.1% to about 8% by weight of a saliva-stimulating agent.
36. The composition of claim 26, wherein the mucoadhesive polymer matrix comprises hydroxypropyl cellulose, a copolymer of N-vinyl-2 -pyrrolidone and vinyl acetate, and hydroxypropyl methylcellulose.
37. The composition of claim 1, wherein the DMTor a pharmaceutically acceptable salt or prodrug thereof is capable of being substantially fully solubilized and released in less than 1 minute following administration of the composition to a patient in need thereof.
38. The composition of claim 1, wherein DMT or a pharmaceutically acceptable salt or prodrug thereof is capable of being substantially fully solubilized and released in greater than 1 minute and less than 20 minutes following administration of the composition to a patient in need thereof.
39. The composition of claim 1, wherein the DMT or a pharmaceutically acceptable salt or prodrug thereof is capable of being substantially fully solubilized and released in greater than 20 minutes and less than 3 hours following administration of the composition to a patient in need thereof.
40. The composition of claim 1, wherein the polymeric carrier matrix is an oral transmucosal film.
41. The composition of claim 40. wherein the film thickness is about 0.01 mm to about 1.5 mm.
42. The composition of claim 41, wherein the film thickness is about 0.05 mm to about 0.4 mm.
43. The composition of claim 40, wherein the loss on drying (LOD) of the film is about 5-11 % w/w.
44. The composition of claim 43, wherein the loss on drying (LOD) of the film is about 7-9 % w/w.
45. The composition of claim 40, comprisng 3-7 mg/cm2 amorphous DMT.
46. The composition of claim 1, wherein the DMT remains in an amorphous state after aging at 25 °C and 60% relative humidity for 6 months.
47. The composition of claim 46, characterized by a powder x-ray diffractogram free of any discernable peaks.
48. The composition of claim 46, characterized by a differential scanning calorimetry (DSC) spectrum for absence of sharp melting endotherm of crystalline DMT and / or indication of phase change (e.g., glass transition temperature).
49. The composition of claim 1, wherein the DMT is capable of remaining in an amorphous state after aging at 40°C and 75% relative humidity for 6 months.
50. The composition of claim 49, characterized by a powder x-ray diffractogram free of any discernable peaks.
51. The composition of claim 49, characterized by a differential scanning calorimetry (DSC) spectrum for absence of sharp melting endotherm of crystalline DMT and or indication of phase change.
52. The composition of claim 51, wherein the indication of phase change is glass transition temperature.
53. A method of treating major depressive disorder, comprising administering a therapeutically effective amount of die composition of claim 1.
54. A method of making a pharmaceutical composition, comprising the steps of: combining N-N-dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof, and excipients in a solvent; and removing the solvent to provide a polymeric matrix comprising an amorphous N-N- dimethyltryptamine or a pharmaceutically acceptable salt or prodrug thereof.
55. The method of claim 54, wherein the solvent comprises methanol and water or water alone.
56. The method of claim 54. wherein the solvent comprises methanol-water in a 50:50 ratio or water alone.
57. The method of claim 54, wherein the method comprises casting the polymeric matrix by removing the solvent to form a film.
58. The method of claim 57, wherein the composition is an oral transmucosal film.
59. The method of claim 57, wherein the film thickness is about 0.01 mm to about 1.5 mm.
60. The method of claim 59, wherein the film thickness is about 0.05 mm to about 0.4 mm.
61. The method of claim 57, wherein the loss on dr ing (LOD) of the film is about 5-11 % w/w.
62. The method of claim 61, wherein the loss on drying (LOD) of the film is about 7-9 % w/w.
63. The method of claim 57, wherein the amorphous DMT content is within 3-7 mg/cm2
64. The method of claim 54, wherein the process comprises spray -drying.
65. A composition prepared according to the method of claim 54.
66. The composition of claim 65, wherein die DMT is capable of remaining in an amorphous state after aging at 25°C and 60% relative humidity for 6 months.
67. The composition of claim 66, characterized by a powder x-ray diffractogram free of any discernable peaks.
68. The composition of claim 66. characterized by a differential scanning calorimetry (DSC) spectrum for absence of sharp melting endotherm of crystalline DMT and /or indication of phase change.
69. The composition of claim 68. wherein the indication of phase change is glass transition temperature.
70. The composition of claim 65, wherein the DMT is capable of emaining in an amorphous state after aging at 40°C and 75% relative humidity for 6 months.
71. The composition of claim 70 characterized by a powder x-ray diffractogram free of any discernable peaks.
'll. The pharmaceutical composition of claim 70, characterized by a differential scanning calorimetry (DSC) spectrum for absence of sharp melting endotherm of crystalline DMT and /or indication of phase change.
73. The composition of claim 70, wherein the indication of phase change is glass transition temperature.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/974,443 | 2022-10-26 | ||
US17/974,443 US20230136824A1 (en) | 2021-04-26 | 2022-10-26 | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024092106A2 true WO2024092106A2 (en) | 2024-05-02 |
WO2024092106A3 WO2024092106A3 (en) | 2024-06-06 |
Family
ID=90832092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/077879 WO2024092106A2 (en) | 2022-10-26 | 2023-10-26 | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024092106A2 (en) |
-
2023
- 2023-10-26 WO PCT/US2023/077879 patent/WO2024092106A2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2436565C2 (en) | Disintegrating oral films | |
JP5786195B2 (en) | Sublingual film | |
JP4850346B2 (en) | Mucosal patch | |
JP5944932B2 (en) | Transmucosal film dosage form | |
EP2640370B1 (en) | Compositions for transdermal delivery of active agents | |
TWI343263B (en) | Patches for mucosa of oral cavity containing fentanyl | |
EP3505161A1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
WO2020086673A1 (en) | Ketamine oral transmucosal delivery system | |
EP4076380B1 (en) | Transmucosal therapeutic system containing agomelatine | |
JP2013515782A (en) | Orally administrable film formulation containing ondansetron | |
US20210244656A1 (en) | Isotretinoin oral-mucosal formulations and methods for using same | |
CN111465391A (en) | Compositions of epinephrine and prodrug with enhanced delivery | |
CN111132670A (en) | Pharmaceutical composition with enhanced penetration | |
WO2021196659A1 (en) | Glycosyl polyether compound liposome, preparation method therefor and medicine thereof | |
US20230321039A1 (en) | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof | |
JP2023545372A (en) | Treatment of bipolar disorder and psychosis with dexmedetomidine hydrochloride | |
JP2019523212A (en) | Fast-acting orally disintegrating film for local anesthetic administration | |
WO2020260726A1 (en) | Transmucosal therapeutic system containing agomelatine | |
JP2010138124A (en) | Oral mucosal patch | |
WO2024092106A2 (en) | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof | |
JP2006070027A (en) | Administration agent to mucous membrane in oral cavity | |
OA20027A (en) | Isotretinoin oral-mucosal formulations and methods for using same. | |
KR20240023530A (en) | Apixaban film products and uses thereof | |
TW201801717A (en) | A fast acting orally disintegrating film for administration of local anesthesia |